<SEC-DOCUMENT>0001837607-26-000005.txt : 20260121
<SEC-HEADER>0001837607-26-000005.hdr.sgml : 20260121
<ACCEPTANCE-DATETIME>20260121160610
ACCESSION NUMBER:		0001837607-26-000005
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20260121
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260121
DATE AS OF CHANGE:		20260121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AEON Biopharma, Inc.
		CENTRAL INDEX KEY:			0001837607
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				853940478
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40021
		FILM NUMBER:		26547846

	BUSINESS ADDRESS:	
		STREET 1:		5 PARK PLAZA
		STREET 2:		SUITE 1750
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		(949) 354-6499

	MAIL ADDRESS:	
		STREET 1:		5 PARK PLAZA
		STREET 2:		SUITE 1750
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Priveterra Acquisition Corp.
		DATE OF NAME CHANGE:	20201222
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aeon-20260121x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.2.0.5 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 1/21/2026 6:23:56 PM -->
<!-- iXBRL Library version: 1.0.9448.42501 -->
<!-- iXBRL Service Job ID: 00000000-0000-0000-0000-000000000000 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:aeon="http://www.aeonbiopharma.com/20260121" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title>AEON Biopharma,&#160;Inc._January 21, 2026</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" name="dei:EntityCentralIndexKey" id="Tc_ZHSRv7qa6kiQXPf21NGegg_2_1">0001837607</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" name="dei:AmendmentFlag" id="Tc__tyqLVL_L021-DJfCIPv5w_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="aeon-20260121.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001837607</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-21</xbrli:startDate><xbrli:endDate>2026-01-21</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><div style="padding-top:1.0px;border-top:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_a3683774_04b4_4fb1_80dc_3cc9af4202ef"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" name="dei:DocumentType" id="Narr_ZCOiB_FG0ESmS4c1w37gug"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_FK3PvGEqwUGBaE-qIUTTQg"><b style="font-weight:bold;">January 21, 2026</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:24pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" name="dei:EntityRegistrantName" id="Narr_i8CLeEAwzk60gLvvEpEoSQ"><b style="font-weight:bold;">AEON Biopharma,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a3df5546_1afe_49c6_8b45_dda32ca530b0"></a><a id="Tc_bQ-rn4dBwEO76aWlVehirw_2_0"></a><a id="Tc_J6WfKiongEuyKHxybG00tA_2_2"></a><a id="Tc_izcV1VTI_E6r6oqOQdSHOg_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:34.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:25.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:36.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:top;width:34.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_GsG4TZm3HEq-0Sj8gPOMrg_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:top;width:25.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" name="dei:EntityFileNumber" id="Tc_wIul5urS3023WFlLrNpl2Q_1_2"><b style="font-size:8pt;font-weight:bold;">001-40021</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:top;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" name="dei:EntityTaxIdentificationNumber" id="Tc_O8VEWr-9_0eeCNEjbwkz_Q_1_4"><b style="font-size:8pt;font-weight:bold;">85-3940478</b></ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:top;width:34.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification Number)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" name="dei:EntityAddressAddressLine1" id="Narr_Iy0d0isM7kiP57tB0nmfuQ"><b style="font-size:8pt;font-weight:bold;">5 Park Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" name="dei:EntityAddressAddressLine2" id="Narr_LdiD9KeyGkiDqvxRHcQQbg"><b style="font-size:8pt;font-weight:bold;">Suite&#160;1750</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" name="dei:EntityAddressCityOrTown" id="Narr_4mSZUgEUyUGq9de_bGGmTw"><b style="font-size:8pt;font-weight:bold;">Irvine</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" name="dei:EntityAddressStateOrProvince" id="Narr_MaKykK7Bf0u7wKjxzKNcQA"><b style="font-size:8pt;font-weight:bold;">CA</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" name="dei:EntityAddressPostalZipCode" id="Narr_vD4tUs0VSk2XS0FYCO-5GA"><b style="font-size:8pt;font-weight:bold;">92614</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(Address of principal executive offices, including Zip Code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" name="dei:CityAreaCode" id="Narr_Rc7nRnq8g0qEh-MjSutF3w"><b style="font-size:8pt;font-weight:bold;">949</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" name="dei:LocalPhoneNumber" id="Narr_vQrtAZE650KwVeLD4lgJ5Q"><b style="font-size:8pt;font-weight:bold;">354-6499</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_S-pw5RMLpUiwl_mtS0OrVQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_4kkJL1O1GE-y_MQxudRyow"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_EVLpDsRgqUOpnHbyOf7SLA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_PtTDm0dsVEK6FGjkngqknA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="font-size:8pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e9e601d6_be32_4696_b167_2f5795049325"></a><a id="Tc_T4z4L8fCyUaM5IxfeSajTw_1_0"></a><a id="Tc_FfIWsI_Fck6DIyCtoW1K4A_1_2"></a><a id="Tc_PTOXKWZOtk2lYlVaTe8ONg_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:34.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:24.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:36.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:34.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:top;width:24.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol</b></p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:top;width:36.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr style=""><td style="vertical-align:top;width:34.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" name="dei:Security12bTitle" id="Tc_98HbwGEvTEebPc4rutnDLw_2_0"><span style="font-size:8pt;">Class&#160;A Common Stock, $0.0001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.76%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" name="dei:TradingSymbol" id="Tc_G3Yw75VYyEy9I7NX4xk_eA_2_2"><span style="font-size:8pt;">AEON</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.73%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_obApG6l6gUy7wKI9LtAPkg_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><span style="font-size:8pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_NJO828BS0kejGfej9vfyHQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="Narr_GVoqwnlynEmjZI58LR5iXA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><div style="padding-bottom:1.0px;border-bottom:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_99bb1556_173c_41a1_b564_585a0390928e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 3.02. Unregistered Sales of Equity Securities.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">As previously disclosed, on December 15, 2025, AEON Biopharma, Inc. (the &#8220;Company&#8221;) and AEON Biopharma Sub, Inc., a subsidiary of the Company, entered into an exchange agreement (the &#8220;Exchange Agreement&#8221;) with Daewoong Pharmaceutical Co., LTD. (&#8220;Daewoong&#8221;), relating to the exchange (the &#8220;Exchange&#8221;) of senior secured convertible notes in the principal amount of up to $15,000,000 (the &#8220;Old Notes&#8221;) which were convertible into shares of Class A common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Exchange Agreement and following approval by the Company&#8217;s stockholders at the Special Meeting (as defined below), on January 21, 2026, for the satisfaction in full of all obligations under the Old Notes, the Company issued to Daewoong (i) 11,918,380 newly issued shares of Common Stock and 11,236,631 pre-funded warrants to purchase shares of Common Stock (the &#8220;Exchange Shares&#8221;), (ii) a new senior secured convertible note in a principal amount of $1,500,000 (the &#8220;New Note&#8221;), and (iii) warrants to purchase up to 8,000,000 shares of Common Stock at an exercise price of $1.09392 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The terms of the securities issued in the Exchange were previously disclosed and summarized in the Current Report on Form 8-K filed with the SEC by the Company on December 15, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;">Based in part upon the representations of Daewoong in the Exchange Agreement, the offering and sale of the securities described above are being offered and sold in a private placement under Section 4(a)(2) of the Securities Act, and have not been registered under the Securities Act, or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Immediately following the closing of the Exchange, there were 24,024,282 shares of Common Stock outstanding on January 21, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1608f992_b2b2_403c_9e80_d841ac268c56"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company held its Special Meeting of Stockholders on January 21, 2026 (the &#8220;Special Meeting&#8221;) as described in the Company&#8217;s proxy statement for the Special Meeting, filed with the SEC on December 29, 2025 (the &#8220;Special Meeting Proxy&#8221;). At the Special Meeting, the Company&#8217;s stockholders considered and approved the AEON Biopharma, Inc. Amended and Restated 2023 Incentive Award Plan (the &#8220;2023 Plan&#8221;). The 2023 Plan was previously approved, subject to stockholder approval, by the Company&#8217;s board of directors on December 2, 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A summary of the terms of the 2023 Plan is set forth in the Special Meeting Proxy in the section titled &#8220;<i style="font-style:italic;">Proposal Three &#8211; the Equity Plan Proposal</i>&#8221; beginning on Page 21 of the Special Meeting Proxy, which is incorporated herein by reference. Such summary and the foregoing description are qualified in their entirety by reference to the text of the 2023 Plan, a copy of which is attached hereto as Exhibit 10.1 and incorporated by reference herein. </p><a id="_67e25676_5ea8_4373_8671_53769bded9b8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 5.07. Submission of Matters to a Vote of Security Holders.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">At the Special Meeting, the stockholders of the Company voted on four proposals as further described in the Special Meeting Proxy. The final results for each proposal voted on by the stockholders at the Special Meeting, as certified by the Company&#8217;s inspector of elections, are set forth below. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Proposal 1: To approve, for purposes of complying with the NYSE American Company Guide, and for all other purposes, (i) the issuance and sale of 4,616,924 shares (the &#8220;Shares&#8221;) of Common Stock, or pre-funded warrants to purchase Common Stock in lieu of the Shares, (ii) warrants to purchase an aggregate of 6,581,829 shares of Common Stock and (iii) shares issuable upon exercise of True-Up Warrants (as defined below) (the &#8220;PIPE Financing Proposal&#8221;). The voting results for the PIPE Financing Proposal were as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:22.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:22.59%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">For</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Against</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Abstain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Broker Non-Vote</b></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:22.59%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';">3,772,647</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.19%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';">2,337,981</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';">5,048</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';">&#8212;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:12pt 0pt 0pt 0pt;">Proposal 2: To approve, for purposes of complying with the NYSE American Company Guide, and for all other purposes, the exchange of the outstanding senior secured convertible notes of the Company held by Daewoong pursuant to an exchange agreement, dated </p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">December 15, 2025, by and between the Company and Daewoong for (i) Exchange Shares, (ii) a new senior secured convertible note in a principal amount of $1,500,000 and (iii) a warrant to purchase 8,000,000 shares of Common Stock (the &#8220;Exchange Proposal&#8221;). The voting results for the Exchange Proposal were as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:22.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:22.59%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">For</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Against</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Abstain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Broker Non-Vote</b></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:22.59%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';">3,788,793</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.19%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';">2,325,814</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';">1,069</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';">&#8212;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;">Proposal 3: To approve the 2023 Plan, to, among other things, increase the number of shares of Common Stock authorized for issuance thereunder (the &#8220;Equity Plan Proposal&#8221;). The voting results for the Equity Plan Proposal were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:22.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:22.59%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">For</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Against</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Abstain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Broker Non-Vote</b></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:22.59%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';">3,426,326</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.19%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';">2,688,150</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';">1,200</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';">&#8212;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;">Proposal 4: To approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the PIPE Financing Proposal, the Exchange Proposal or the Equity Plan Proposal (the &#8220;Adjournment Proposal&#8221;). The voting results for the Adjournment Proposal were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:22.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:22.59%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">For</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Against</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Abstain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Aptos Narrow';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Broker Non-Vote</b></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:22.59%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';">3,691,133</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.19%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';">2,418,859</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';">5,684</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:22.6%;background:#deeaf6;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';">&#8212;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_12764b70_d017_492c_b4d8_0a31f3c41c67"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 7.01. Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;">On January 21, 2026, the Company issued a press release announcing (i) the approval of the proposals at the Special Meeting, (ii) the consummation of the Exchange, and (iii) the expected timing for the second closing the Private Placement (as defined below). A copy of the press release is furnished as Exhibit 99.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;">The information furnished under this Item 7.01 (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</p><a id="_4fd8a116_d15d_4191_85b3_b8887c28c7fc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#8201;8.01. Other Events.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amendment to License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Exchange, on January 21, 2026, the Company entered into a Fifth Amendment to the License and Supply Agreement (the &#8220;License Agreement Amendment&#8221;) with Daewoong, which amends the License and Supply Agreement, by and between the Company and Daewoong, dated December 20, 2019, as amended on July 29, 2022, January 8, 2023, April 24, 2023 and March 19, 2024. Pursuant to the terms of the License Agreement Amendment, the definition of &#8220;Notes&#8221; reflects the Exchange and the Termination Purchase Right (as defined in the License Agreement Amendment) will terminate and expire upon Daewoong&#8217;s sale of 50% of its Common Stock, including Common Stock held by its affiliates and Common Stock that would be issued upon conversion of the New Note. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The foregoing description of the terms of the License Agreement Amendment does not purport to be complete and is qualified in its entirety by the full text of the License Agreement Amendment, which is attached hereto as Exhibit 10.2 and incorporated by reference herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Closing of Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As previously disclosed, on November 13, 2025, the Company entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain investors (the &#8220;Investors&#8221;) whereby the Company will issue and sell to the Investors in a private placement (the &#8220;Private Placement&#8221;): (i) shares of Common Stock, (ii) pre-funded warrants (the &#8220; Pre-Funded Warrants&#8221;) to purchase shares of Common Stock, (iii) warrants (the &#8220;Warrants&#8221;) to purchase shares of Common Stock, and (iv) True-Up Warrants (as defined in the Securities Purchase Agreement) to purchase shares of Common Stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The first closing of the Private Placement occurred on November 18, 2025. Following approval of the PIPE Financing Proposal at the Special Meeting and the consummation of the Exchange, the second closing of the Private Placement is expected to occur the week of January 26, 2026 (the &#8220;Second Closing&#8221;). At the Second Closing, subject to customary closing conditions set forth in the Securities </p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Purchase Agreement, the Company expects to issue and sell 4,616,924 Shares (or Pre-Funded Warrants in lieu of Shares), 6,581,829 Warrants and up to 6,581,829 True-Up Warrants to the Investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Securities Purchase Agreement was previously filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC by the Company on November 13, 2025. </p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_840e625e_fe8d_4525_af04_56ded27f8a7a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9.01. Financial Statement and Exhibits. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(d) Exhibits.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:0.55%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td colspan="2" style="vertical-align:middle;width:2.2%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:0.42%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:28.68%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:29.4%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:29.4%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"/><td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"/><td style="vertical-align:middle;width:0.55%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"/><td colspan="2" style="vertical-align:middle;width:2.2%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"/><td style="vertical-align:middle;width:0.42%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"/><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"/><td style="vertical-align:middle;width:28.68%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"/><td style="vertical-align:middle;width:29.4%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"/><td style="vertical-align:middle;width:29.4%;margin:0pt;padding:0.75pt 1pt 0.75pt 1pt;"/></tr><tr style=""><td colspan="4" style="vertical-align:bottom;width:10%;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit No.</b></p></td><td colspan="3" style="vertical-align:middle;width:2.5%;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"/><td colspan="3" style="vertical-align:bottom;width:87.5%;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Description</b></p></td></tr><tr style=""><td colspan="4" style="vertical-align:bottom;width:10%;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.1</p></td><td colspan="3" style="vertical-align:middle;width:2.5%;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:87.5%;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="aeon-20260121xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">AEON Biopharma, Inc. Amended and Restated 2023 Incentive Award Plan.</span></a></p></td></tr><tr style=""><td colspan="4" style="vertical-align:bottom;width:10%;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.2</p></td><td colspan="3" style="vertical-align:middle;width:2.5%;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:87.5%;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="aeon-20260121xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to the License and Supply Agreement, dated as of January 21, 2026, by and between the Company and Daewoong Pharmaceutical Co., Ltd.</span></a></p></td></tr><tr style=""><td colspan="4" style="vertical-align:bottom;width:10%;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">99.1</p></td><td colspan="3" style="vertical-align:middle;width:2.5%;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:87.5%;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="aeon-20260121xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, January 21, 2026.</span></a></p></td></tr><tr style=""><td colspan="4" style="vertical-align:bottom;width:10%;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">104</p></td><td colspan="3" style="vertical-align:middle;width:2.5%;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:87.5%;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_1ec724aa_165f_4a3b_ab2a_a3b1175a9b6b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">AEON Biopharma,&#160;Inc.</b></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: January 21, 2026</p></td><td style="vertical-align:top;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Robert Bancroft</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert Bancroft</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>aeon-20260121xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 1/21/2026 06:23:55 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:11pt;font-variant:small-caps;font-weight:bold;text-align:center;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt -6pt 0pt -6pt;padding:6pt 6pt 12pt 6pt;"><a name="_Hlk215479433"></a><b style="font-family:'Times New Roman Bold';font-variant:normal;font-weight:bold;text-transform:uppercase;">AEON Biopharma, inc.</b></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:11pt;font-variant:small-caps;font-weight:bold;padding-bottom:6pt;padding-left:6pt;padding-right:6pt;text-align:center;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt -6pt 12pt -6pt;">AMENDED AND RESTATED 2023 INCENTIVE AWARD PLAN</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE I.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>Purpose </div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Plan&#8217;s purpose is to enhance the Company&#8217;s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. &#160;Capitalized terms used in the Plan are defined in Article&#160;XI. This Plan amends and restates in its entirety the AEON Biopharma, Inc. 2023 Incentive Award Plan (the &#8220;<font style="font-style:italic;font-weight:bold;">Original Plan</font>&#8221;) which became effective on July 21, 2023 (the &#8220;<font style="font-style:italic;font-weight:bold;">Original Effective Date</font>&#8221;).</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE II.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>Eligibility</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Service Providers are eligible to be granted Awards under the Plan, subject to the limitations described herein.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE III.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>Administration and Delegation </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.1</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration</u>. &#160;The Plan is administered by the Administrator. &#160;The Administrator has authority to determine which Service Providers receive Awards, grant Awards and set Award terms and conditions, subject to the conditions and limitations in the Plan. &#160;The Administrator also has the authority to take all actions and make all determinations under the Plan, to interpret the Plan and Award Agreements and to adopt, amend and repeal Plan administrative rules, guidelines and practices as it deems advisable. &#160;The Administrator may correct defects and ambiguities, supply omissions and reconcile inconsistencies in the Plan or any Award Agreement as it deems necessary or appropriate to administer the Plan and any Awards. &#160;The Administrator&#8217;s determinations under the Plan are in its sole discretion and will be final and binding on all persons having or claiming any interest in the Plan or any Award.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.2</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appointment of Committees</u>. &#160;To the extent Applicable Laws permit, the Board or the Administrator may delegate any or all of its powers under the Plan to one or more Committees or committees of officers of the Company or any of its Subsidiaries. &#160;The Board or the Administrator, as applicable, may rescind any such delegation, abolish any such committee or Committee and/or re-vest in itself any previously delegated authority at any time. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE IV.</font><font style="font-weight:normal;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font>Stock Available for Awards</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.1</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Number of Shares</u>. &#160;Subject to adjustment under Article&#160;VIII and the terms of this Article&#160;IV, Awards may be made under the Plan covering up to the Overall Share Limit. &#160;Prior Plan Awards will remain subject to the terms of the Prior Plan. &#160;Shares issued under the Plan may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.2</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Share Recycling</u>. &#160;If, after the Original Effective Date, all or any part of an Award or Prior Plan Award expires, lapses or is terminated, exchanged for or settled in cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, in any case, in a manner that results in the Company acquiring Shares covered by the Award or Prior Plan Award at a price not greater than the price </div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(as adjusted to reflect any Equity Restructuring) paid by the Participant for such Shares or not issuing any Shares covered by the Award or Prior Plan Award, the unused Shares covered by the Award or Prior Plan Award will, as applicable, become or again be available for Award grants under the Plan. &#160;Further, Shares delivered (either by actual delivery or attestation) to the Company by a Participant to satisfy the applicable exercise or purchase price of an Award or Prior Plan Award and/or to satisfy any applicable tax withholding obligation with respect to an Award or Prior Plan Award (including Shares retained by the Company from the Award or Prior Plan Award being exercised or purchased and/or creating the tax obligation) will, as applicable, become or again be available for Award grants under the Plan. &#160;The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards or Prior Plan Awards shall not count against the Overall Share Limit. &#160;Notwithstanding anything to the contrary contained herein, the following Shares shall not be added to the Shares authorized for grant under Section 4.1 and shall not be available for future grants of Awards: (a) Shares subject to a Stock Appreciation Right that are not issued in connection with the stock settlement of the Stock Appreciation Right on exercise thereof; and (b) Shares purchased on the open market with the cash proceeds from the exercise of Options (including Prior Plan Awards).</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.3</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Incentive Stock Option Limitations</u>. &#160;Notwithstanding anything to the contrary herein, no more than 20,000,000 Shares may be issued pursuant to the exercise of Incentive Stock Options. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.4</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Substitute Awards</u>. &#160;In connection with an entity&#8217;s merger or consolidation with the Company or the Company&#8217;s acquisition of an entity&#8217;s property or stock, the Administrator may grant Awards in substitution for any options or other stock or stock-based awards granted before such merger or consolidation by such entity or its affiliate. &#160;Substitute Awards may be granted on such terms as the Administrator deems appropriate, notwithstanding limitations on Awards in the Plan. &#160;Substitute Awards will not count against the Overall Share Limit (nor shall Shares subject to a Substitute Award be added to the Shares available for Awards under the Plan as provided above), except that Shares acquired by exercise of substitute Incentive Stock Options will count against the maximum number of Shares that may be issued pursuant to the exercise of Incentive Stock Options under the Plan. Additionally, in the event that a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines has shares available under a pre-existing plan approved by stockholders and not adopted in contemplation of such acquisition or combination, the shares available for grant pursuant to the terms of such pre-existing plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration payable to the holders of common stock of the entities party to such acquisition or combination) may be used for Awards under the Plan and shall not reduce the Shares authorized for grant under the Plan (and Shares subject to such Awards shall not be added to the Shares available for Awards under the Plan as provided above); provided that Awards using such available shares shall not be made after the date awards or grants could have been made under the terms of the pre-existing plan, absent the acquisition or combination, and shall only be made to individuals who were not Employees, Consultants or Directors prior to such acquisition or combination.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.5</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Employee Director Compensation</u>. &#160;Notwithstanding any provision to the contrary in the Plan, the Administrator may establish compensation for non-employee Directors from time to time, subject to the limitations in the Plan. &#160;The Administrator will from time to time determine the terms, conditions and amounts of all such non-employee Director compensation in its discretion and pursuant to the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, provided that the sum of any cash compensation, or other compensation, and the value (determined as of the grant date in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of Awards granted to a non-employee Director as compensation for services as a non-employee Director during any calendar year of the Company may not exceed $600,000 (increased to $750,000 in the calendar year of a non-employee Director&#8217;s initial service as a non-employee director or any calendar year during which a non-employee Director serves as chairman of the Board or lead independent Director), which limits shall </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">2</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">not apply to the compensation for any non-employee Director of the Company who serves in any capacity in addition to that of a non-employee Director for which he or she receives additional compensation or any compensation paid to any non-employee Director prior to the calendar year following the calendar year in which the Plan&#8217;s effective date occurs. &#160;The Administrator may make exceptions to this limit for individual non-employee Directors in extraordinary circumstances, as the Administrator may determine in its discretion, provided that the non-employee Director receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving non-employee Directors. </font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE V.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>Stock Options and Stock Appreciation Rights</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.1</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u>. &#160;The Administrator may grant Options or Stock Appreciation Rights to Service Providers subject to the limitations in the Plan, including any limitations in the Plan that apply to Incentive Stock Options. &#160;A Stock Appreciation Right will entitle the Participant (or other person entitled to exercise the Stock Appreciation Right) to receive from the Company upon exercise of the exercisable portion of the Stock Appreciation Right an amount determined by multiplying the excess, if any, of the Fair Market Value of one Share on the date of exercise over the exercise price per Share of the Stock Appreciation Right by the number of Shares with respect to which the Stock Appreciation Right is exercised, subject to any limitations of the Plan or that the Administrator may impose and payable in cash, Shares valued at Fair Market Value or a combination of the two as the Administrator may determine or provide in the Award Agreement. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.2</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Price</u>. &#160;The Administrator will establish each Option&#8217;s and Stock Appreciation Right&#8217;s exercise price and specify the exercise price in the Award Agreement. &#160;The exercise price will not be less than 100% of the Fair Market Value on the grant date of the Option (subject to Section 5.6) or Stock Appreciation Right. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.3</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Duration</u>. &#160;Each Option or Stock Appreciation Right will be exercisable at such times and as specified in the Award Agreement, provided that, subject to Section 5.6, the term of an Option or Stock Appreciation Right will not exceed ten years. &#160;Notwithstanding the foregoing and unless determined otherwise by the Company, in the event that on the last business day of the term of an Option or Stock Appreciation Right (other than an Incentive Stock Option) (i) the exercise of the Option or Stock Appreciation Right is prohibited by Applicable Law, as determined by the Company, or (ii) Shares may not be purchased or sold by the applicable Participant due to any Company insider trading policy (including blackout periods) or a &#8220;lock-up&#8221; agreement undertaken in connection with an issuance of securities by the Company, the term of the Option or Stock Appreciation Right shall be extended until the date that is 30 days after the end of the legal prohibition, black-out period or lock-up agreement, as determined by the Company; provided, however, in no event shall the extension last beyond the ten year term of the applicable Option or Stock Appreciation Right. &#160;Notwithstanding the foregoing, to the extent permitted under Applicable Laws, if the Participant, prior to the end of the term of an Option or Stock Appreciation Right, violates the non-competition, non-solicitation, confidentiality or other similar restrictive covenant provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company or any of its Subsidiaries, the right of the Participant and the Participant&#8217;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall terminate immediately upon such violation, unless the Company otherwise determines. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.4</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise</u>. &#160;Options and Stock Appreciation Rights may be exercised by delivering to the Company a written notice of exercise, in a form the Administrator approves (which may be electronic), signed by the person authorized to exercise the Option or Stock Appreciation Right, together with, as applicable, payment in full (i) as specified in Section&#160;5.5 for the number of Shares for which the Award is </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">3</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">exercised and (ii) as specified in Section&#160;9.5 for any applicable taxes. &#160;Unless the Administrator otherwise determines, an Option or Stock Appreciation Right may not be exercised for a fraction of a Share.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.5</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Ref528758801"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment Upon Exercise</u>. &#160;Subject to Sections 9.10 and&#160;10.8, any Company insider trading policy (including blackout periods) and Applicable Laws, the exercise price of an Option must be paid by: </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>cash, wire transfer of immediately available funds or by check payable to the order of the Company, provided that the Company may limit the use of one of the foregoing payment forms if one or more of the payment forms below is permitted;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>if there is a public market for Shares at the time of exercise, unless the Company otherwise determines, (A) delivery (including electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to pay the exercise price, or (B) the Participant&#8217;s delivery to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to pay the exercise price; provided that such amount is paid to the Company at such time as may be required by the Administrator; &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>to the extent permitted by the Administrator, delivery (either by actual delivery or attestation) of Shares owned by the Participant valued at their Fair Market Value;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font>to the extent permitted by the Administrator, surrendering Shares then issuable upon the Option&#8217;s exercise valued at their Fair Market Value on the exercise date; </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font>to the extent permitted by the Administrator, delivery of a promissory note or any other property that the Administrator determines is good and valuable consideration; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font>to the extent permitted by the Company, any combination of the above payment forms approved by the Administrator.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.6</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Terms of Incentive Stock Options</u>. &#160;The Administrator may grant Incentive Stock Options only to employees of the Company, any of its present or future parent or subsidiary corporations, as defined in Sections&#160;424(e) or (f) of the Code, respectively, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code. &#160;If an Incentive Stock Option is granted to a Greater Than 10% Stockholder, the exercise price will not be less than 110% of the Fair Market Value on the Option&#8217;s grant date, and the term of the Option will not exceed five years. &#160;All Incentive Stock Options will be subject to and construed consistently with Section&#160;422 of the Code. &#160;By accepting an Incentive Stock Option, the Participant agrees to give prompt notice to the Company of dispositions or other transfers (other than in connection with a Change in Control) of Shares acquired under the Option made within (i) two years from the grant date of the Option or (ii) one year after the transfer of such Shares to the Participant, specifying the date of the disposition or other transfer and the amount the Participant realized, in cash, other property, assumption of indebtedness or other consideration, in such disposition or other transfer. &#160;Neither the Company nor the Administrator will be liable to a Participant, or any other party, if an Incentive Stock Option fails or ceases to qualify as an &#8220;incentive stock option&#8221; under Section&#160;422 of the Code. &#160;Any Incentive Stock Option or portion thereof that fails to qualify as an &#8220;incentive stock option&#8221; under Section&#160;422 of the Code for any reason, including becoming exercisable with respect to Shares having a fair market value exceeding the $100,000 limitation under Treasury Regulation Section&#160;1.422-4, will be a Non-Qualified Stock Option.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE VI.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>Restricted Stock; Restricted Stock Units</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">4</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.1</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u>. &#160;The Administrator may grant Restricted Stock, or the right to purchase Restricted Stock, to any Service Provider, subject to the Company&#8217;s right to repurchase all or part of such Shares at their issue price or other stated or formula price from the Participant (or to require forfeiture of such Shares) if conditions the Administrator specifies in the Award Agreement are not satisfied before the end of the applicable restriction period or periods that the Administrator establishes for such Award. &#160;In addition, the Administrator may grant to Service Providers Restricted Stock Units, which may be subject to vesting and forfeiture conditions during the applicable restriction period or periods, as set forth in an Award Agreement. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.2</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Stock</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dividends</u>. &#160;Participants holding Shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to such Shares, unless the Administrator provides otherwise in the Award Agreement. &#160;In addition, unless the Administrator provides otherwise, if any dividends or distributions are paid in Shares, or consist of a dividend or distribution to holders of Common Stock of property other than an ordinary cash dividend, the Shares or other property will be subject to the same restrictions on transferability and forfeitability as the Shares of Restricted Stock with respect to which they were paid. &#160;Notwithstanding anything to the contrary herein, with respect to any award of Restricted Stock, dividends which are paid to holders of Common Stock prior to vesting shall only be paid out to a Participant holding such Restricted Stock to the extent that the vesting conditions are subsequently satisfied. &#160;All such dividend payments will be made no later than March 15 of the calendar year following the calendar year in which the right to the dividend payment becomes nonforfeitable.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Certificates</u>. &#160;The Company may require that the Participant deposit in escrow with the Company (or its designee) any stock certificates issued in respect of Shares of Restricted Stock, together with a stock power endorsed in blank.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.3</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Stock Units.</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Settlement</u>. &#160;The Administrator may provide that settlement of Restricted Stock Units will occur upon or as soon as reasonably practicable after the Restricted Stock Units vest or will instead be deferred, on a mandatory basis or at the Participant&#8217;s election, in a manner intended to comply with Section&#160;409A.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stockholder Rights</u>. &#160;A Participant will have no rights of a stockholder with respect to Shares subject to any Restricted Stock Unit unless and until the Shares are delivered in settlement of the Restricted Stock Unit.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE VII.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>Other Stock or Cash Based Awards; DIVIDEND EQUIVALENTS<font style="font-weight:normal;"> </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">7.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Stock or Cash Based Awards</u>. &#160;Other Stock or Cash Based Awards may be granted to Participants, including Awards entitling Participants to receive Shares to be delivered in the future and including annual or other periodic or long-term cash bonus awards (whether based on specified Performance Criteria or otherwise), in each case subject to any conditions and limitations in the Plan. Such Other Stock or Cash Based Awards will also be available as a payment form in the settlement of other Awards, as standalone payments and as payment in lieu of compensation to which a Participant is otherwise entitled. &#160;Other Stock or Cash Based Awards may be paid in Shares, cash or other property, as the Administrator determines. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">7.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dividend Equivalents</u>. &#160;A grant of Restricted Stock Units or Other Stock or Cash Based Award may provide a Participant with the right to receive Dividend Equivalents, and no Dividend </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">5</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Equivalents shall be payable with respect to Options or Stock Appreciation Rights. &#160;Dividend Equivalents may be paid currently or credited to an account for the Participant, settled in cash or Shares and subject to the same restrictions on transferability and forfeitability as the Award with to which the Dividend Equivalents are paid and subject to other terms and conditions as set forth in the Award Agreement. &#160;Notwithstanding anything to the contrary herein, Dividend Equivalents with respect to an Award shall only be paid out to a Participant to the extent that the vesting conditions are subsequently satisfied. &#160;All such Dividend Equivalent payments will be made no later than March 15 of the calendar year following the calendar year in which the right to the Dividend Equivalent payment becomes nonforfeitable, unless determined otherwise by the Administrator or unless deferred in a manner intended to comply with Section&#160;409A.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE VIII.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Ref528758860"></a>Adjustments for Changes in Common Stock <br>and Certain Other Events</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.1</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Ref528758911"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Restructuring</u>. &#160;In connection with any Equity Restructuring, notwithstanding anything to the contrary in this Article&#160;VIII, the Administrator will equitably adjust each outstanding Award as it deems appropriate to reflect the Equity Restructuring, which may include (if applicable) adjusting the number and type of securities subject to each outstanding Award, the Award&#8217;s exercise price or grant price and/or applicable performance goals, granting new Awards to Participants, and making a cash payment to Participants. &#160;The adjustments provided under this Section&#160;8.1 will be nondiscretionary and final and binding on the affected Participant and the Company; provided that the Administrator will determine whether an adjustment is equitable.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.2</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Ref528758958"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Corporate Transactions</u>. &#160;In the event of any dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), reorganization, merger, consolidation, combination, amalgamation, repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or sale or exchange of Common Stock or other securities of the Company, Change in Control, issuance of warrants or other rights to purchase Common Stock or other securities of the Company, other similar corporate transaction or event, other unusual or nonrecurring transaction or event affecting the Company or its financial statements or any change in any Applicable Laws or accounting principles, the Administrator, on such terms and conditions as it deems appropriate, either by the terms of the Award or by action taken in connection with the occurrence of such transaction or event (any action to give effect to a change in Applicable Law or accounting principles may be made within a reasonable period of time after such change), is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to (x) prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any Award granted or issued under the Plan, (y) to facilitate such transaction or event or (z) give effect to such changes in Applicable Laws or accounting principles: &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>To provide for the cancellation of any such Award in exchange for either an amount of cash or other property with a value equal to the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#8217;s rights under the vested portion of such Award, as applicable; provided that, if the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#8217;s rights, in any case, is equal to or less than zero, then the Award may be terminated without payment; provided, further, that Awards held by members of the Board will be deemed settled in Shares on or immediately prior to the applicable event if the Administrator takes action under this clause (a); &#160;</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">6</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>To provide that such Award shall vest and, to the extent applicable, be exercisable as to all Shares covered thereby, notwithstanding anything to the contrary in the Plan or the provisions of such Award;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>To provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, or equivalent value thereof in cash, with appropriate adjustments as to the number and kind of shares and/or applicable exercise or purchase price, in all cases, as determined by the Administrator; &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font>To make adjustments in the number and type of Shares (or other securities or property) subject to outstanding Awards and/or with respect to which Awards may be granted under the Plan (including, but not limited to, adjustments of the limitations in Article&#160;IV on the maximum number and kind of shares which may be issued) and/or in the terms and conditions of (including the grant or exercise price or applicable performance goals), and the criteria included in, outstanding Awards; &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font>To replace such Award with other rights or property selected by the Administrator; and/or</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font>To provide that the Award will terminate and cannot vest, be exercised or become payable after the applicable event.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.3</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Non-Assumption in a Change in Control</u><font style="text-decoration-color:#000000;text-decoration-line:none;">. &#160;Notwithstanding the provisions of Section 8.2, if a Change in Control occurs and a Participant&#8217;s Awards are not continued, converted, assumed, or replaced with a substantially similar award by (a) the Company, or (b) a successor entity or its parent or subsidiary (an &#8220;</font><font style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Assumption</font><font style="text-decoration-color:#000000;text-decoration-line:none;">&#8221;), and provided that the Participant has not had a Termination of Service, then, immediately prior to the Change in Control, such Awards shall become fully vested, exercisable and/or payable, as applicable, and all forfeiture, repurchase and other restrictions on such Awards shall lapse (provided that, to the extent the vesting of any such Award is subject to the satisfaction of specified performance goals, such Award shall vest and all performance goals or other vesting criteria will be deemed achieved at the target level of performance, unless specifically provided otherwise under the applicable Award Agreement or other written agreement between the Participant and the Company or any Subsidiary, as applicable). &#160;In addition, to the extent an Assumption does not occur, such Awards shall be canceled upon the consummation of the Change in Control in exchange for the right to receive the Change in Control consideration payable to other holders of Common Stock (i) which may be on such terms and conditions as apply generally to holders of Common Stock under the Change in Control documents (including, without limitation, any escrow, earn-out or other deferred consideration provisions) or such other terms and conditions as the Administrator may provide, and (ii) determined by reference to the number of Shares subject to such Awards and net of any applicable exercise price; </font><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:none;">provided that</i><font style="text-decoration-color:#000000;text-decoration-line:none;"> to the extent that any Awards constitute &#8220;nonqualified deferred compensation&#8221; that may not be paid upon the Change in Control under Section 409A without the imposition of taxes thereon under Section 409A, the timing of such payments shall be governed by the applicable Award Agreement (subject to any deferred consideration provisions applicable under the Change in Control documents); and </font><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:none;">provided, further</i><font style="text-decoration-color:#000000;text-decoration-line:none;">, that if the amount to which a Participant would be entitled upon the settlement or exercise of such Award at the time of the Change in Control is equal to or less than zero, then such Award may be terminated without payment. &#160;The Administrator shall determine whether an Assumption of an Award has occurred in connection with a Change in Control.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.4</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administrative Stand Still</u>. &#160;In the event of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other extraordinary transaction or change affecting </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">7</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">the Shares or the Share price, including any Equity Restructuring or any securities offering or other similar transaction, for administrative convenience, the Administrator may refuse to permit the exercise of any Award for up to 60 days before or after such transaction.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.5</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u>. &#160;Except as expressly provided in the Plan or the Administrator&#8217;s action under the Plan, no Participant will have any rights due to any subdivision or consolidation of Shares of any class, dividend payment, increase or decrease in the number of Shares of any class or dissolution, liquidation, merger, or consolidation of the Company or other corporation. &#160;Except as expressly provided with respect to an Equity Restructuring under Section&#160;8.1 or the Administrator&#8217;s action under the Plan, no issuance by the Company of Shares of any class, or securities convertible into Shares of any class, will affect, and no adjustment will be made regarding, the number of Shares subject to an Award or the Award&#8217;s grant or exercise price. &#160;The existence of the Plan, any Award Agreements and the Awards granted hereunder will not affect or restrict in any way the Company&#8217;s right or power to make or authorize (i) any adjustment, recapitalization, reorganization or other change in the Company&#8217;s capital structure or its business, (ii) any merger, consolidation dissolution or liquidation of the Company or sale of Company assets or (iii) any sale or issuance of securities, including securities with rights superior to those of the Shares or securities convertible into or exchangeable for Shares. &#160;The Administrator may treat Participants and Awards (or portions thereof) differently under this Article&#160;VIII.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE IX.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>General Provisions Applicable to Awards<font style="font-weight:normal;"> </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.1</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transferability</u>. &#160;Except as the Administrator may determine or provide in an Award Agreement or otherwise for Awards other than Incentive Stock Options, Awards may not be sold, assigned, transferred, pledged or otherwise encumbered, either voluntarily or by operation of law, except for certain Designated Beneficiary designations, by will or the laws of descent and distribution, or, subject to the Administrator&#8217;s consent, pursuant to a domestic relations order, and, during the life of the Participant, will be exercisable only by the Participant. &#160;Any permitted transfer of an Award hereunder shall be without consideration, except as required by Applicable Law. &#160;References to a Participant, to the extent relevant in the context, will include references to a Participant&#8217;s authorized transferee that the Administrator specifically approves.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.2</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Documentation</u>. &#160;Each Award will be evidenced in an Award Agreement, which may be written or electronic, as the Administrator determines. &#160;Each Award may contain terms and conditions in addition to those set forth in the Plan. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.3</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Discretion</u>. &#160;Except as the Plan otherwise provides, each Award may be made alone or in addition or in relation to any other Award. &#160;The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions thereof) uniformly. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.4</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Status</u>. &#160;The Administrator will determine how the disability, death, retirement, an authorized leave of absence or any other change or purported change in a Participant&#8217;s Service Provider status affects an Award and the extent to which, and the period during which, the Participant, the Participant&#8217;s legal representative, conservator, guardian or Designated Beneficiary may exercise rights under the Award, if applicable.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.5</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Ref528758820"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding</u>. &#160;Each Participant must pay the Company, or make provision satisfactory to the Administrator for payment of, any taxes required by Applicable Law to be withheld in connection with such Participant&#8217;s Awards by the date of the event creating the tax liability. &#160;The Company may deduct an amount sufficient to satisfy such tax obligations based on the applicable statutory withholding rates (or such other rate as may be determined by the Company after considering any accounting consequences or costs) </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">8</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">from any payment of any kind otherwise due to a Participant. &#160;In the absence of a contrary determination by the Company (or, with respect to withholding pursuant to clause (ii) below with respect to Awards held by individuals subject to Section 16 of the Exchange Act, a contrary determination by the Administrator), all tax withholding obligations will be calculated based on the minimum applicable statutory withholding rates. &#160;Subject to Section 10.8 and any Company insider trading policy (including blackout periods), Participants may satisfy such tax obligations (i) in cash, by wire transfer of immediately available funds, by check made payable to the order of the Company, provided that the Company may limit the use of the foregoing payment forms if one or more of the payment forms below is permitted, (ii) to the extent permitted by the Administrator, in whole or in part by delivery of Shares, including Shares delivered by attestation and Shares retained from the Award creating the tax obligation, valued at their fair market value on the date of delivery, (iii) subject to Section 9.10, if there is a public market for Shares at the time the tax obligations are satisfied, unless the Company otherwise determines, (A) delivery (including electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to satisfy the tax obligations, or (B) delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to satisfy the tax withholding; provided that such amount is paid to the Company at such time as may be required by the Administrator, or (iv) to the extent permitted by the Company, any combination of the foregoing payment forms approved by the Administrator. &#160;Notwithstanding any other provision of the Plan, the number of Shares which may be so delivered or retained pursuant to clause (ii) of the immediately preceding sentence shall be limited to the number of Shares which have a fair market value on the date of delivery or retention no greater than the aggregate amount of such liabilities based on the maximum applicable statutory withholding rate in the applicable jurisdiction at the time of such withholding (or such other rate as may be required to avoid the liability classification of the applicable award under generally accepted accounting principles in the United States of America). &#160;Subject to Section 9.10, if any tax withholding obligation will be satisfied under clause (ii) above by the Company&#8217;s retention of Shares from the Award creating the tax obligation and there is a public market for Shares at the time the tax obligation is satisfied, the Company may elect to instruct any brokerage firm determined acceptable to the Company for such purpose to sell on the applicable Participant&#8217;s behalf some or all of the Shares retained and to remit the proceeds of the sale to the Company or its designee, and each Participant&#8217;s acceptance of an Award under the Plan will constitute the Participant&#8217;s authorization to the Company and instruction and authorization to such brokerage firm to complete the transactions described in this sentence. </font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.6</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment of Award</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">; Prohibition on Repricing</u>. &#160;The Administrator may amend, modify or terminate any outstanding Award, including by substituting another Award of the same or a different type, changing the exercise or settlement date, and converting an Incentive Stock Option to a Non-Qualified Stock Option. &#160;The Participant&#8217;s consent to such action will be required unless (i) the action, taking into account any related action, does not materially and adversely affect the Participant&#8217;s rights under the Award, or (ii) the change is permitted under Article&#160;VIII or pursuant to Section&#160;10.6. &#160;Notwithstanding the foregoing or anything in the Plan to the contrary, except in connection with a corporate transaction involving the Company (including, without limitation, any stock dividend, stock split, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination or exchange of shares), the terms of outstanding Awards may not be amended to reduce the exercise price per share of outstanding Options or Stock Appreciation Rights or cancel outstanding Options or Stock Appreciation Rights in exchange for cash, other Awards or Options or Stock Appreciation Rights with an exercise price per share that is less than the exercise price per share of the original Options or Stock Appreciation Rights without the approval of the stockholders of the Company.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.7</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions on Delivery of Stock</u>. &#160;The Company will not be obligated to deliver any Shares under the Plan or remove restrictions from Shares previously delivered under the Plan until (i)&#160;all Award conditions have been met or removed to the Company&#8217;s satisfaction, (ii)&#160;as determined by the Company, </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">9</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">all other legal matters regarding the issuance and delivery of such Shares have been satisfied, including any applicable securities laws and stock exchange or stock market rules and regulations, and (iii)&#160;the Participant has executed and delivered to the Company such representations or agreements as the Administrator deems necessary or appropriate to satisfy any Applicable Laws. &#160;The Company&#8217;s inability to obtain authority from any regulatory body having jurisdiction, which the Administrator determines is necessary to the lawful issuance and sale of any securities, will relieve the Company of any liability for failing to issue or sell such Shares as to which such requisite authority has not been obtained.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.8</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acceleration</u>. &#160;The Administrator may at any time provide that any Award will become immediately vested and fully or partially exercisable, free of some or all restrictions or conditions, or otherwise fully or partially realizable.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.9</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash Settlement</u><font style="text-decoration-color:#000000;text-decoration-line:none;">. &#160;Without limiting the generality of any other provision of the Plan, the Administrator may provide, in an Award Agreement or subsequent to the grant of an Award, in its discretion, that any Award may be settled in cash, Shares or a combination thereof.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.10</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Broker-Assisted Sales</u><font style="text-decoration-line:none;">. &#160;In the event of a broker-assisted sale of Shares in connection with the payment of amounts owed by a Participant under or with respect to the Plan or Awards, including amounts to be paid under the final sentence of Section&#160;9.5 above: (a) any Shares to be sold through the broker-assisted sale will be sold on the day the payment first becomes due, or as soon thereafter as practicable; (b) such Shares may be sold as part of a block trade with other Participants in the Plan in which all Participants receive an average price; (c) the applicable Participant will be responsible for all broker&#8217;s fees and other costs of sale, and by accepting an Award, each Participant agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale; (d) to the extent the Company or its designee receives proceeds of such sale that exceed the amount owed, the Company will pay such excess in cash to the applicable Participant as soon as reasonably practicable; (e) the Company and its designees are under no obligation to arrange for such sale at any particular price; and (f) in the event the proceeds of such sale are insufficient to satisfy the Participant&#8217;s applicable obligation, the Participant may be required to pay immediately upon demand to the Company or its designee an amount in cash sufficient to satisfy any remaining portion of the Participant&#8217;s obligation. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE X.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>Miscellaneous<font style="font-weight:normal;"> </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.1</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Right to Employment or Other Status</u>. &#160;No person will have any claim or right to be granted an Award, and the grant of an Award will not be construed as giving a Participant the right to continued employment or any other relationship with the Company or any of its Subsidiaries. &#160;The Company and its Subsidiaries expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan or any Award, except as expressly provided in an Award Agreement or in the Plan.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.2</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Rights as Stockholder; Certificates</u>. &#160;Subject to the Award Agreement, no Participant or Designated Beneficiary will have any rights as a stockholder with respect to any Shares to be distributed under an Award until becoming the record holder of such Shares. &#160;Notwithstanding any other provision of the Plan, unless the Administrator otherwise determines or Applicable Laws require, the Company will not be required to deliver to any Participant certificates evidencing Shares issued in connection with any Award and instead such Shares may be recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator). &#160;The Company may place legends on stock certificates issued under the Plan that the Administrator deems necessary or appropriate to comply with Applicable Laws.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">10</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.3</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Ref528758757"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date and Term of Plan</u>. &#160;Unless earlier terminated by the Board, the Plan (as amended and restated) will become effective on the date on which the Plan is approved by the Company&#8217;s stockholders (the &#8220;<font style="font-style:italic;font-weight:bold;">Effective Date</font>&#8221;) and will remain in effect until the tenth anniversary of the Effective Date. &#160;Notwithstanding anything to the contrary in the Plan, an Incentive Stock Option may not be granted under the Plan after 10 years from the earlier of (i) the date the Board adopted the Plan (as amended and restated) or (ii) the date the Company&#8217;s stockholders approved the Plan (as amended and restated), but Awards previously granted may extend beyond that date in accordance with the Plan. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.4</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment of Plan</u>. &#160;The Administrator may amend, suspend or terminate the Plan at any time; provided that no amendment, other than an increase to the Overall Share Limit, may materially and adversely affect any Award outstanding at the time of such amendment without the affected Participant&#8217;s consent. &#160;No Awards may be granted under the Plan during any suspension period or after the Plan&#8217;s termination. &#160;Awards outstanding at the time of any Plan suspension or termination will continue to be governed by the Plan and the Award Agreement, as in effect before such suspension or termination. &#160;The Board will obtain stockholder approval of any Plan amendment to the extent necessary to comply with Applicable Laws.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.5</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Provisions for Foreign Participants</u>. &#160;The Administrator may modify Awards granted to Participants who are foreign nationals or employed outside the United States or establish subplans or procedures under the Plan to address differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters.<a name="_Ref528759021"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.6</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;409A</u>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u>. &#160;The Company intends that all Awards be structured to comply with, or be exempt from, Section&#160;409A, such that no adverse tax consequences, interest, or penalties under Section&#160;409A apply. &#160;Notwithstanding anything in the Plan or any Award Agreement to the contrary, the Administrator may, without a Participant&#8217;s consent, amend this Plan or Awards, adopt policies and procedures, or take any other actions (including amendments, policies, procedures and retroactive actions) as are necessary or appropriate to preserve the intended tax treatment of Awards, including any such actions intended to (A)&#160;exempt this Plan or any Award from Section&#160;409A, or (B)&#160;comply with Section&#160;409A, including regulations, guidance, compliance programs and other interpretative authority that may be issued after an Award&#8217;s grant date. &#160;The Company makes no representations or warranties as to an Award&#8217;s tax treatment under Section&#160;409A or otherwise. &#160;The Company will have no obligation under this Section&#160;10.6 or otherwise to avoid the taxes, penalties or interest under Section&#160;409A with respect to any Award and will have no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to constitute noncompliant &#8220;nonqualified deferred compensation&#8221; subject to taxes, penalties or interest under Section&#160;409A.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation from Service</u>. &#160;If an Award constitutes &#8220;nonqualified deferred compensation&#8221; under Section&#160;409A, any payment or settlement of such Award upon a termination of a Participant&#8217;s Service Provider relationship will, to the extent necessary to avoid taxes under Section&#160;409A, be made only upon the Participant&#8217;s &#8220;separation from service&#8221; (within the meaning of Section&#160;409A), whether such &#8220;separation from service&#8221; occurs upon or after the termination of the Participant&#8217;s Service Provider relationship. &#160;For purposes of this Plan or any Award Agreement relating to any such payments or benefits, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms means a &#8220;separation from service.&#8221;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments to Specified Employees</u>. &#160;Notwithstanding any contrary provision in the Plan or any Award Agreement, any payment(s) of &#8220;nonqualified deferred compensation&#8221; required to be made under an Award to a &#8220;specified employee&#8221; (as defined under Section&#160;409A and as the Administrator </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">11</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">determines) due to his or her &#8220;separation from service&#8221; will, to the extent necessary to avoid taxes under Section&#160;409A(a)(2)(B)(i) of the Code, be delayed for the six-month period immediately following such &#8220;separation from service&#8221; (or, if earlier, until the specified employee&#8217;s death) and will instead be paid (as set forth in the Award Agreement) on the day immediately following such six-month period or as soon as administratively practicable thereafter (without interest). &#160;Any payments of &#8220;nonqualified deferred compensation&#8221; under such Award payable more than six months following the Participant&#8217;s &#8220;separation from service&#8221; will be paid at the time or times the payments are otherwise scheduled to be made. &#160;Furthermore, notwithstanding any contrary provision of the Plan or any Award Agreement, any payment of &#8220;nonqualified deferred compensation&#8221; under the Plan that may be made in installments shall be treated as a right to receive a series of separate and distinct payments. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.7</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitations on Liability</u>. &#160;Notwithstanding any other provisions of the Plan and to the fullest extent permitted by Applicable Laws and the Company&#8217;s certificate of incorporation and bylaws, (a) &#160;no individual acting as a director, officer, other employee or agent of the Company or any Subsidiary will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan or any Award, and such individual will not be personally liable with respect to the Plan because of any contract or other instrument executed in his or her capacity as an Administrator, director, officer, other employee or agent of the Company or any Subsidiary, and (b) the Company will indemnify and hold harmless each director, officer, other employee and agent of the Company or any Subsidiary that has been or will be granted or delegated any duty or power relating to the Plan&#8217;s administration or interpretation, against any cost or expense (including attorneys&#8217; fees) or liability (including any sum paid in settlement of a claim with the Administrator&#8217;s approval) arising from any act or omission concerning this Plan unless arising from such person&#8217;s own fraud or bad faith.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.8</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Ref528758832"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lock-Up Period</u>. &#160;The Company may, at the request of any underwriter representative or otherwise, in connection with registering the offering of any Company securities under the Securities Act, prohibit Participants from, directly or indirectly, selling or otherwise transferring any Shares or other Company securities during a period of up to 180 days following the effective date of a Company registration statement filed under the Securities Act, or such longer period as determined by the underwriter.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.9</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Ref528759063"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Data Privacy</u>. &#160;As a condition for receiving any Award, each Participant explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of personal data as described in this section by and among the Company and its Subsidiaries and affiliates exclusively for implementing, administering and managing the Participant&#8217;s participation in the Plan. &#160;The Company and its Subsidiaries and affiliates may hold certain personal information about a Participant, including the Participant&#8217;s name, address and telephone number; birthdate; social security, insurance number or other identification number; salary; nationality; job title(s); any Shares held in the Company or its Subsidiaries and affiliates; and Award details, to implement, manage and administer the Plan and Awards (the &#8220;<font style="font-style:italic;font-weight:bold;">Data</font>&#8221;). &#160;The Company and its Subsidiaries and affiliates may transfer the Data amongst themselves as necessary to implement, administer and manage a Participant&#8217;s participation in the Plan, and the Company and its Subsidiaries and affiliates may transfer the Data to third parties assisting the Company with Plan implementation, administration and management. &#160;These recipients may be located in the Participant&#8217;s country, or elsewhere, and the Participant&#8217;s country may have different data privacy laws and protections than the recipients&#8217; country. &#160;By accepting an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, to implement, administer and manage the Participant&#8217;s participation in the Plan, including any required Data transfer to a broker or other third party with whom the Company or the Participant may elect to deposit any Shares. &#160;The Data related to a Participant will be held only as long as necessary to implement, administer, and manage the Participant&#8217;s participation in the Plan. &#160;A Participant may, at any time, view the Data that the Company holds regarding such Participant, request additional information about the storage and processing of the Data regarding such Participant, recommend any necessary corrections to the Data regarding the Participant or refuse or </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">12</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">withdraw the consents in this Section&#160;10.9 in writing, without cost, by contacting the local human resources representative. &#160;If the Participant refuses or withdraws the consents in this Section&#160;10.9, the Company may cancel Participant&#8217;s ability to participate in the Plan and, in the Administrator&#8217;s discretion, the Participant may forfeit any outstanding Awards. &#160;For more information on the consequences of refusing or withdrawing consent, Participants may contact their local human resources representative.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.10</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. &#160;If any portion of the Plan or any action taken under it is held illegal or invalid for any reason, the illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provisions had been excluded, and the illegal or invalid action will be null and void.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.11</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Documents</u>. &#160;If any contradiction occurs between the Plan and any Award Agreement or other written agreement between a Participant and the Company (or any Subsidiary) that the Administrator has approved, the Plan will govern, unless it is expressly specified in such Award Agreement or other written document that a specific provision of the Plan will not apply.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.12</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. &#160;The Plan and all Awards will be governed by and interpreted in accordance with the laws of the State of Delaware, disregarding any state&#8217;s choice-of-law principles requiring the application of a jurisdiction&#8217;s laws other than the State of Delaware.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.13</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Claw-back Provisions</u>. &#160;All Awards (including, without limitation, any proceeds, gains or other economic benefit actually or constructively received by Participant upon any receipt or exercise of any Award or upon the receipt or sale of any Shares underlying the Award) shall be subject to the provisions of any claw-back policy implemented by the Company, including, without limitation, the Company&#8217;s Policy for Recovery of Erroneously Awarded Compensation and any claw-back policy adopted to comply with Applicable Laws as and to the extent set forth in such claw-back policy or the Award Agreement. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.14</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Titles and Headings</u>. &#160;The titles and headings in the Plan are for convenience of reference only and, if any conflict, the Plan&#8217;s text, rather than such titles or headings, will control.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.15</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conformity to Applicable Laws</u>. &#160;Participant acknowledges that the Plan is intended to conform to the extent necessary with Applicable Laws. &#160;Notwithstanding anything herein to the contrary, the Plan and all Awards will be administered only in conformance with Applicable Laws. &#160;To the extent Applicable Laws permit, the Plan and all Award Agreements will be deemed amended as necessary to conform to Applicable Laws. For the avoidance of doubt and notwithstanding anything herein to the contrary, any provisions relating to exculpation or indemnification of directors, officers, employees or others under the Plan and all Awards will be administered and construed in accordance with Applicable Laws and the Company&#8217;s certificate of incorporation, bylaws, and other governing documents.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.16</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Ref528758666"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Relationship to Other Benefits</u>. &#160;No payment under the Plan will be taken into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except as expressly provided in writing in such other plan or an agreement thereunder.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">10.17</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stockholder Approval</u>. The Plan (as amended and restated) will be submitted for the approval of the Company&#8217;s stockholders within twelve (12) months after the date of the Board&#8217;s initial adoption of the Plan (as amended and restated). Awards may be granted or awarded under the Plan (as amended and restated) and subject to the terms and conditions of the Original Plan following the Board&#8217;s adoption of the Plan (as amended and restated) unless and until the Plan (as amended and restated) receives stockholder approval. Awards granted from and after stockholder approval of the Plan (as amended and restated) will be subject to the terms and conditions of the Plan (as amended and restated). If the Plan (as </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">13</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">amended and restated) is not approved by stockholders within twelve (12) months after its adoption by the Board, then the Original Plan shall continue on its existing terms and conditions and the Plan (as amended and restated) shall be of no force or effect.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE XI.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Ref528758565"></a>Definitions<font style="font-weight:normal;"> </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As used in the Plan, the following words and phrases will have the following meanings:</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.1</font>&#8220;<font style="font-style:italic;font-weight:bold;">Administrator</font>&#8221; means the Board or a Committee to the extent that the Board&#8217;s powers or authority under the Plan have been delegated to such Committee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.2</font>&#8220;<font style="font-style:italic;font-weight:bold;">Applicable Laws</font>&#8221; means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities, corporate, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where Awards are granted.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.3</font>&#8220;<font style="font-style:italic;font-weight:bold;">Award</font>&#8221; means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Dividend Equivalents, or Other Stock or Cash Based Awards.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.4</font>&#8220;<font style="font-style:italic;font-weight:bold;">Award Agreement</font>&#8221; means a written agreement evidencing an Award, which may be electronic, that contains such terms and conditions as the Administrator determines, consistent with and subject to the terms and conditions of the Plan.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.5</font>&#8220;<font style="font-style:italic;font-weight:bold;">Board</font>&#8221; means the Board of Directors of the Company.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.6</font>&#8220;<font style="font-style:italic;font-weight:bold;">Change in Control</font>&#8221; means and includes each of the following: </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i) and (ii) of subsection&#160;(c) below) whereby any &#8220;person&#8221; or related &#8220;group&#8221; of &#8220;persons&#8221; (as such terms are used in Sections&#160;13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries or a &#8220;person&#8221; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#8217;s securities outstanding immediately after such acquisition; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board together with any new Director(s) (other than a Director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a) or (c)) whose election by the Board or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least two-thirds of the Directors then still in office who either were Directors at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x)&#160;a merger, consolidation, reorganization, or business combination or (y)&#160;a sale or other disposition of all or substantially all of the </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">14</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;">Company&#8217;s assets in any single transaction or series of related transactions or (z)&#160;the acquisition of assets or stock of another entity, in each case other than a transaction:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font>which results in the Company&#8217;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#8217;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#8220;<font style="font-style:italic;font-weight:bold;">Successor Entity</font>&#8221;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#8217;s outstanding voting securities immediately after the transaction, and</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font>after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that no person or group shall be treated for purposes of this clause (ii) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction. &#160;</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, if a Change in Control constitutes a payment event with respect to any Award (or portion of any Award) that provides for the deferral of compensation that is subject to Section&#160;409A, to the extent required to avoid the imposition of additional taxes under Section&#160;409A, the transaction or event described in subsection&#160;(a), (b) or (c) with respect to such Award (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing of such Award (or portion thereof) if such transaction also constitutes a &#8220;change in control event,&#8221; as defined in Treasury Regulation Section&#160;1.409A-3(i)(5).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Administrator shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a &#8220;change in control event&#8221; as defined in Treasury Regulation Section&#160;1.409A-3(i)(5) shall be consistent with such regulation.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.7</font><font style="white-space:pre-wrap;"> </font>&#8220;<font style="font-style:italic;font-weight:bold;">Code</font>&#8221; means the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.8</font>&#8220;<font style="font-style:italic;font-weight:bold;">Committee</font>&#8221; means one or more committees or subcommittees of the Board, which may include one or more Company directors or executive officers, to the extent Applicable Laws permit. &#160;To the extent required to comply with the provisions of Rule 16b-3, it is intended that each member of the Committee will be, at the time the Committee takes any action with respect to an Award that is subject to Rule 16b-3, a &#8220;non-employee director&#8221; within the meaning of Rule 16b-3; however, a Committee member&#8217;s failure to qualify as a &#8220;non-employee director&#8221; within the meaning of Rule 16b-3 will not invalidate any Award granted by the Committee that is otherwise validly granted under the Plan. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.9</font>&#8220;<font style="font-style:italic;font-weight:bold;">Common Stock</font>&#8221; means the Class A common stock of the Company, par value of $0.0001 per share. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.10</font>&#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221; means AEON Biopharma, Inc., a Delaware corporation, or any successor.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.11</font><font style="white-space:pre-wrap;"> </font>&#8220;<font style="font-style:italic;font-weight:bold;">Consultant</font>&#8221; means any consultant or advisor, engaged by the Company or any of its Subsidiaries to render services to such entity, who qualifies as a consultant or advisor under the applicable rules of Form S-8 Registration Statement.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">15</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.12</font>&#8220;<font style="font-style:italic;font-weight:bold;">Designated Beneficiary</font>&#8221; means the beneficiary or beneficiaries the Participant designates, in a manner the Administrator determines, to receive amounts due or exercise the Participant&#8217;s rights if the Participant dies or becomes incapacitated. &#160;Without a Participant&#8217;s effective designation, &#8220;Designated Beneficiary&#8221; will mean the Participant&#8217;s estate.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.13</font>&#8220;<font style="font-style:italic;font-weight:bold;">Director</font>&#8221; means a Board member.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.14</font>&#8220;<font style="font-style:italic;font-weight:bold;">Dividend Equivalents</font>&#8221; means a right granted to a Participant under the Plan to receive the equivalent value (in cash or Shares) of dividends paid on Shares.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.15</font>&#8220;<font style="font-style:italic;font-weight:bold;">Employee</font>&#8221; means any employee of the Company or its Subsidiaries.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.16</font>&#8220;<font style="font-style:italic;font-weight:bold;">Equity Restructuring</font>&#8221; means, as determined by the Administrator, a non-reciprocal transaction between the Company and its stockholders, such as a stock dividend, stock split, spin-off or recapitalization through a large, nonrecurring cash dividend, or other large, nonrecurring cash dividend, that affects the Shares (or other securities of the Company) or the share price of Common Stock (or other securities of the Company) and causes a change in the per share value of the Common Stock underlying outstanding Awards.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.17</font>&#8220;<font style="font-style:italic;font-weight:bold;">Exchange Act</font>&#8221; means the Securities Exchange Act of 1934, as amended.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.18</font>&#8220;<font style="font-style:italic;font-weight:bold;">Fair Market Value</font>&#8221; means, as of any date, the value of a Share of Common Stock determined as follows: (a)&#160;if the Common Stock is listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Common Stock as quoted on such exchange for such date, or if no sale occurred on such date, the last day preceding such date during which a sale occurred, as reported in <i style="font-style:italic;">The Wall Street Journal</i> or another source the Administrator deems reliable; (b)&#160;if the Common Stock is not traded on a stock exchange but is quoted on a national market or other quotation system, the closing sales price on such date, or if no sales occurred on such date, then on the last date preceding such date during which a sale occurred, as reported in <i style="font-style:italic;">The Wall Street Journal </i>or another source the Administrator deems reliable; or (c) without an established market for the Common Stock, the Administrator will determine the Fair Market Value in its discretion. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.19</font>&#8220;<font style="font-style:italic;font-weight:bold;">Fully-Diluted Shares</font>&#8221; means, as of any given date, (i) shares of Preferred Stock and shares of Common Stock outstanding on such date, (ii) shares of Common Stock subject to compensatory equity awards (including stock options and restricted stock units) outstanding on such date, with (A) performance-based compensatory equity awards calculated at the &#8220;target&#8221; level of performance and (B) shares of Common Stock subject to stock options calculated on a &#8220;net exercised&#8221; basis as of the applicable date, assuming shares are surrendered having a Fair Market Value on such date equal to the exercise price of such options (rounded up to the nearest whole Share, and determined without regard to the vested status of the stock option) and (iii) shares issuable upon the exercise or settlement of other equity securities with respect to which shares of Common Stock have not actually been issued and the conversion of all convertible securities into shares of Common Stock, in each case, counted on an as-converted-to shares of Common Stock basis; provided, however, that shares of Common Stock subject to warrants outstanding on such date shall not be included in the determination of Fully-Diluted Shares.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.20</font>&#8220;<font style="font-style:italic;font-weight:bold;">Greater Than 10% Stockholder</font>&#8221; means an individual then owning (within the meaning of Section&#160;424(d) of the Code) more than 10% of the total combined voting power of all classes of stock of the Company or its parent or subsidiary corporation, as defined in Section&#160;424(e) and (f) of the Code, respectively.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">16</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.21</font>&#8220;<font style="font-style:italic;font-weight:bold;">Incentive Stock Option</font>&#8221; means an Option intended to qualify as an &#8220;incentive stock option&#8221; as defined in Section&#160;422 of the Code.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.22</font>&#8220;<font style="font-style:italic;font-weight:bold;">Non-Qualified Stock Option</font>&#8221; means an Option, or portion thereof, not intended or not qualifying as an Incentive Stock Option.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.23</font>&#8220;<font style="font-style:italic;font-weight:bold;">Option</font>&#8221; means an option to purchase Shares, which will either be an Incentive Stock Option or a Non-Qualified Stock Option.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.24</font>&#8220;<font style="font-style:italic;font-weight:bold;">Other Stock or Cash Based Awards</font>&#8221; means cash awards, awards of Shares, and other awards valued wholly or partially by referring to, or are otherwise based on, Shares or other property awarded to a Participant under Article&#160;VII.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.25</font><a name="_Hlk215398216"></a>&#8220;<font style="font-style:italic;font-weight:bold;">Overall Share Limit</font>&#8221; means the sum of (a) [_______]<sup style="font-size:8.25pt;vertical-align:top;"><a style="vertical-align:super;" href="#footnote-2">1</a></sup> Shares, (b) any Shares which, as of the Original Effective Date, are subject to Prior Plan Awards which, on or following the Original Effective Date, become available for issuance under the Plan pursuant to Article IV (which aggregate number added to the Overall Share Limit shall not exceed 4,556,783 Shares) and (c) an annual increase on the first day of each calendar year beginning on and including January 1, 2027 and ending on and including January 1, 2033 equal to the lesser of (i) a number of Shares equal to 5% of the number of Fully-Diluted Shares on the final day of the immediately preceding calendar year and (ii) such smaller number of Shares as is determined by the Board. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.26</font>&#8220;<font style="font-style:italic;font-weight:bold;">Participant</font>&#8221; means a Service Provider who has been granted an Award.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.27</font>&#8220;<font style="font-style:italic;font-weight:bold;">Performance Criteria</font>&#8221; mean the criteria (and adjustments) that the Administrator may select for an Award to establish performance goals for a performance period, which may include the following: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, and non-cash equity-based compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including but not limited to gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholders&#8217; equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research, development, regulatory, commercial, or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals; <font style="vertical-align:baseline;">customer satisfaction/growth; customer service</font>; <font style="vertical-align:baseline;">employee satisfaction</font>; <font style="vertical-align:baseline;">recruitment and maintenance of personnel; human c</font>apital<font style="vertical-align:baseline;"> managemen</font>t;<font style="vertical-align:baseline;"> supervision of litigation and other legal matters</font>; <font style="vertical-align:baseline;">strategic partnerships and transactions</font>;<font style="vertical-align:baseline;"> financial ratios (including those measuring liquidity, activity, profitability or leverage)</font>;<font style="vertical-align:baseline;"> debt levels or reductions</font>;<font style="vertical-align:baseline;"> sales-related goals</font>;<font style="vertical-align:baseline;"> financing and other capital raising transactions</font>; <font style="vertical-align:baseline;">cash on hand</font>;<font style="vertical-align:baseline;"> acquisition activity</font>;<font style="vertical-align:baseline;"> investment sourcing activity; and marketing initiatives,</font> any of which may be measured in absolute terms or as compared to any incremental increase or decrease. &#160;Such performance goals also may be based solely by reference to the Company&#8217;s performance or the performance of a Subsidiary, </div><div style="margin-bottom:5pt;margin-top:15pt;width:25%;border-bottom:1px solid black;"></div><a name="footnote-2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:6pt 0pt 0pt 0pt;"><sup style="font-size:7.5pt;vertical-align:top;">1</sup> NTD: This amount will equal the sum of (i) the current plan reserve (53,332 shares), plus (ii) any shares that have been added to the plan pursuant to the evergreen on January 1, 2024 (23,357 shares) and January 1, 2025 (27,198 shares), plus any shares that are added on January 1, 2026 to the extent the amended plan becomes effective on or after such date, plus (iii) the number of new shares to be added to the plan (17,288,059 shares). </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">17</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;">division, business segment or business unit of the Company or a Subsidiary, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.28</font>&#8220;<font style="font-style:italic;font-weight:bold;">Plan</font>&#8221; means this Amended and Restated 2023 Incentive Award Plan.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.29</font>&#8220;<font style="font-style:italic;font-weight:bold;">Preferred Stock</font>&#8221; means the preferred stock of the Company, par value of $0.0001 per share.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.30</font>&#8220;<font style="font-style:italic;font-weight:bold;">Prior Plan</font>&#8221; means the AEON Biopharma, Inc. Amended and Restated 2019 Incentive Award Plan.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.31</font>&#8220;<font style="font-style:italic;font-weight:bold;">Prior Plan Award</font>&#8221; means an award outstanding under the Prior Plan as of the Original Effective Date. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.32</font>&#8220;<font style="font-style:italic;font-weight:bold;">Restricted Stock</font>&#8221; means Shares awarded to a Participant under Article&#160;VI subject to certain vesting conditions and other restrictions.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.33</font>&#8220;<font style="font-style:italic;font-weight:bold;">Restricted Stock Unit</font>&#8221; means an unfunded, unsecured right to receive, on the applicable settlement date, one Share or an amount in cash or other consideration determined by the Administrator to be of equal value as of such settlement date awarded to a Participant under Article&#160;VI subject to certain vesting conditions and other restrictions.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.34</font>&#8220;<font style="font-style:italic;font-weight:bold;">Rule 16b-3</font>&#8221; means Rule 16b-3 promulgated under the Exchange Act.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.35</font>&#8220;<font style="font-style:italic;font-weight:bold;">Section&#160;409A</font>&#8221; means Section&#160;409A of the Code and all regulations, guidance, compliance programs and other interpretative authority thereunder.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.36</font>&#8220;<font style="font-style:italic;font-weight:bold;">Securities Act</font>&#8221; means the Securities Act of 1933, as amended.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.37</font>&#8220;<font style="font-style:italic;font-weight:bold;">Service Provider</font>&#8221; means an Employee, Consultant or Director.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.38</font>&#8220;<font style="font-style:italic;font-weight:bold;">Shares</font>&#8221; means shares of Common Stock.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.39</font>&#8220;<font style="font-style:italic;font-weight:bold;">Stock Appreciation Right</font>&#8221; means a stock appreciation right granted under Article&#160;V.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.40</font>&#8220;<font style="font-style:italic;font-weight:bold;">Subsidiary</font>&#8221; means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of all classes of securities or interests in one of the other entities in such chain.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.41</font>&#8220;<font style="font-style:italic;font-weight:bold;">Substitute Awards</font>&#8221; means Awards granted or Shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.42</font>&#8220;<font style="font-style:italic;font-weight:bold;">Termination of Service</font>&#8221; means the date the Participant ceases to be a Service Provider.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-variant:small-caps;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">*&#160;*&#160;*&#160;*&#160;*</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">18</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>aeon-20260121xex10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 1/21/2026 06:23:55 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:right;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">AEON BIOPHARMA, INC.</b></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">FIFTH AMENDMENT</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TO THE </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">LICENSE AND SUPPLY AGREEMENT</b></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;text-indent:40pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">This Fifth Amendment to the License and Supply Agreement (this &quot;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Fifth Amendment</font><font style="font-family:'Times New Roman','Times','serif';">&quot;), is made and entered into as of [Month] [Day], 2026 (&quot;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Fifth Amendment Effective Date</font><font style="font-family:'Times New Roman','Times','serif';">&quot;), by and between AEON</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Biopharma Sub, Inc. (previously known as AEON Biopharma, Inc.), a Delaware corporation (&quot;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">AEON</font><font style="font-family:'Times New Roman','Times','serif';">&quot;), and Daewoong Pharmaceutical Co., Ltd., a corporation organized and existing under the laws of the Republic of Korea (&quot;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Daewoong</font><font style="font-family:'Times New Roman','Times','serif';">&quot;).</font></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;text-indent:44pt;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">WHEREAS:</b><font style="font-family:'Times New Roman','Times','serif';"> AEON Biopharma, Inc., a Delaware corporation (&quot;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">AEON Parent</font><font style="font-family:'Times New Roman','Times','serif';">&quot;) and Daewoong have entered into that certain Exchange Agreement, dated as of December 12, 2025 (the &quot;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Exchange Agreement</font><font style="font-family:'Times New Roman','Times','serif';">&quot;) relating to the exchange of certain existing notes for, among other things, a new senior secured convertible note in the principal amount of $1,500,000 (the &quot;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">New Note</font><font style="font-family:'Times New Roman','Times','serif';">&quot;);</font></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;text-indent:44pt;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">WHEREAS:</b><font style="font-family:'Times New Roman','Times','serif';"> AEON and Daewoong entered into that certain License and Supply Agreement, dated as of December 20, 2019, as amended by that certain First Amendment dated as of July 29, 2022, that certain Second Amendment dated as of January 8, 2023, that certain Third Amendment dated as of April 24, 2023, and that certain Fourth Amendment dated as of March 19, 2024 (collectively, the &quot;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">License Agreement</font><font style="font-family:'Times New Roman','Times','serif';">&quot;); and</font></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;text-indent:44pt;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">WHEREAS:</b><font style="font-family:'Times New Roman','Times','serif';"> In connection with the entry into the Exchange Agreement by AEON Parent and Daewoong and the issuance of the New Note thereunder, AEON and Daewoong desire to amend the License Agreement as set forth herein to reflect the refinancing and exchange of the previous notes.</font></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;text-indent:44pt;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">NOW, THEREFORE:</b><font style="font-family:'Times New Roman','Times','serif';"> For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto hereby covenant and agree to be bound as follows:</font></p><div style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;margin-bottom:8pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:22pt;text-indent:0pt;white-space:nowrap;">1.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capitalized Terms</u><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> Capitalized terms used herein and not otherwise defined herein shall have the respective meanings assigned to them in the License Agreement. All references to the term &quot;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Agreement</font><font style="font-family:'Times New Roman','Times','serif';">&quot; in the License Agreement shall be deemed to include all of the terms and conditions of this Fifth Amendment.</font></div><div style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;margin-bottom:8pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:22pt;text-indent:0pt;white-space:nowrap;">2.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</u><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">The License Agreement is hereby amended and restated as follows:</font></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">i.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Purchase Right Update</u><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> The reference to the &quot;Notes&quot; in the last sentence of Section 16.4 of the License Agreement (as added by the Fourth Amendment) is hereby amended to refer to the &quot;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;">New Note</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&quot; (as defined in the recitals to this Fifth Amendment). Accordingly, the last sentence of Section 16.4 is hereby amended and restated in its entirety as follows:</font></td></tr></table><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 90pt;"><font style="font-family:'Times New Roman','Times','serif';margin-bottom:8pt;margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;margin:0pt 0pt 8pt 90pt;"><font style="font-family:'Times New Roman','Times','serif';">&quot;The Termination Purchase Right shall terminate and expire upon the earliest to occur of the time at which DAEWOONG and Daewoong Co., LTD., collectively, hold less than fifty percent (50%) of the sum of (x) AEON common stock</font> <font style="font-family:'Times New Roman','Times','serif';">(including AEON common stock acquirable from prefunded warrants owned) held by DAEWOONG and Daewoong Co., LTD. on the Fifth Amendment Effective Date, and (y) AEON common stock that DAEWOONG would be issued upon a conversion of the New Note (as defined in the Fifth Amendment to this Agreement).&quot;</font></p><div style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;margin-bottom:8pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:22pt;text-indent:0pt;white-space:nowrap;">3.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Further Amendment</u><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> Except as expressly amended or modified hereby, all terms and conditions of the License Agreement (as amended) are hereby ratified and confirmed and shall remain in full force and effect. In the event of a conflict between the terms of the License Agreement and the terms of this Fifth Amendment, the terms of this Fifth Amendment shall control.</font></div><div style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:22pt;text-indent:0pt;white-space:nowrap;">4.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> This Fifth Amendment may be executed in counterparts, and execution by each </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">1</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:right;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';">of the parties hereto of any one of such counterparts will constitute due execution of this Fifth Amendment. Each such counterpart hereof shall be deemed to be an original instrument, and all such counterparts together shall constitute but one agreement. Execution and delivery of this Fifth Amendment by facsimile or other electronic means (e.g., PDF) by either party hereto shall be legal, valid, and binding to the same extent as an original signature.</font></div><div style="margin-top:8pt;"></div><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</font></p><p style="display:none;line-height:0pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:right;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">IN WITNESS WHEREOF</b><font style="font-family:'Times New Roman','Times','serif';">, each of the undersigned has executed this Fifth Amendment to the License and Supply Agreement as of the Fifth Amendment Effective Date.</font></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">AEON BIOPHARMA SUB, INC.</b></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">By: </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">_/s/ Robert Bancroft________</u></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Name: Robert Bancroft</font></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Title: Chief Executive Officer</font></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:8pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Signature Page to Fifth Amendment to the License and Supply Agreement</font></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:right;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">IN WITNESS WHEREOF</b><font style="font-family:'Times New Roman','Times','serif';">, each of the undersigned has executed this Fifth Amendment to the License and Supply Agreement as of the Fifth Amendment Effective Date.</font></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">DAEWOONG PHARMACEUTICAL CO., LTD.</b></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">By: </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">_/s/ Seongsoo Park___________________</u><font style="font-family:'Times New Roman','Times','serif';"> </font></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Name: Seongsoo Park</font></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Title: President &amp; CEO</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:8pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Signature Page to Fifth Amendment to the License and Supply Agreement</font></p><p style="font-family:'\00b9d1\00c740 \00ace0\00b515';font-size:11pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:avoid;width:75.81%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>aeon-20260121xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 1/21/2026 06:23:55 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:22.3pt;min-height:49.7pt;width:100%;"><div style="clear:both;"></div><div style="clear:left;float:left;height:16.3pt;width:0pt;"></div><div style="clear:left;float:left;height:24.15pt;margin-left:27.75pt;margin-right:9pt;margin-top:16.3pt;width:99.08pt;z-index:251658240;"><div style="height:24.15pt;left:0pt;padding-bottom:0pt;position:relative;width:99.08pt;"><img src="aeon-20260121xex99d1001.jpg" alt="Graphic" style="height:24.15pt;width:99.08pt;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt -36pt;"><font style="font-weight:bold;margin-bottom:0pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt -36pt;"><font style="display:inline-block;width:270pt;"></font><font style="display:inline-block;width:164.9pt;"></font><b style="font-weight:bold;">PRESS RELEASE</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;line-height:1.19;text-align:center;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-weight:normal;">- </font><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;font-weight:normal;">AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes</i><font style="font-family:'Calibri','Helvetica','sans-serif';font-weight:normal;"> -</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;line-height:1.19;text-align:center;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-weight:normal;">- </font><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;font-weight:normal;">Separately, AEON shareholders today voted in favor of the proposals required to complete the transactions announced in November, including the consummation of the PIPE financing and the related Daewoong note exchange</i><font style="font-family:'Calibri','Helvetica','sans-serif';font-weight:normal;"> -</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">IRVINE, Calif., January 21, 2026</b><font style="font-family:'Calibri','Helvetica','sans-serif';"> &#8211; AEON Biopharma, Inc. (&#8220;AEON&#8221; or the &#8220;Company&#8221;) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX</font><font style="font-family:'Symbol';font-size:12pt;">&#210;</font><font style="font-family:'Calibri','Helvetica','sans-serif';"> (onabotulinumtoxinA), today reported on two separate positive events for the Company:</font></p><div style="margin-top:14pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-left:18pt;margin-top:14pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">AEON confirmed that earlier today it held its scheduled BPD Type 2a meeting with FDA, in line with prior guidance. The Company looks forward to commenting on the meeting&#8217;s substance and outcome following receipt of the official meeting minutes from the U.S. Food and Drug Administration (&#8220;FDA&#8221;). &#160;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">AEON also held today a special meeting at which shareholders voted to approve the completion of the transactions announced in November, including the remaining issuances related to the Company&#8217;s private investment in public equity (&#8220;PIPE&#8221;) financing and the related exchange of the Company&#8217;s convertible notes held by Daewoong Pharmaceutical Co., Ltd. (&#8220;Daewoong&#8221;). &#160;As previously disclosed, the Daewoong note exchange, which closed today following shareholder approval, will substantially reduce the Company&#8217;s outstanding debt and further simplify AEON&#8217;s capital structure. &#160;AEON expects to proceed with the second closing of the PIPE financing on or around Tuesday, January 27, 2026, subject to customary closing conditions. </font></div><div style="margin-top:14pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;We are encouraged by the continued progress we are making early in 2026. The completion of our BPD Type 2a meeting with FDA represents an important procedural milestone, and we now look forward to receiving the official meeting minutes within approximately 30 days, which we expect will help inform next steps for the development of ABP-450, our biosimilar to BOTOX&#174;,&#8221; said Rob Bancroft, President &amp; Chief Executive Officer of AEON. &#8220;Additionally, we are thankful to our shareholders for their support of the transactions we announced in November, which strengthen our balance sheet, simplify our capitalization structure and position the company to continue executing on our biosimilar program.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:14pt 0pt 6pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About the U.S. Biosimilar Pathway</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:5pt 0pt 6pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">The U.S. Food and Drug Administration (&#8220;FDA&#8221;) regulates biosimilars under the Public Health Service Act&#8217;s 351(k) pathway, which require developers to demonstrate that a proposed product is highly similar to an approved reference biologic with no clinically meaningful differences in safety, purity, or potency. Analytical similarity is the scientific foundation of this process, representing the most critical and data-intensive phase of development. Once analytical comparability across key quality attributes is established, subsequent FDA interactions focus on confirming whether any residual uncertainty requires limited clinical evaluation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:5pt 0pt 6pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About AEON Biopharma</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:5pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">AEON Biopharma is a biopharmaceutical company seeking accelerated and full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX</font><font style="font-family:'Symbol';">&#210;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. &#160;The Company&#8217;s lead asset is ABP-450 for debilitating medical conditions. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau&#174;. ABP-450 is manufactured by Daewoong Pharmaceutical in compliance with current </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-size:11pt;"><a name="TrailerStart"></a></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:8pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.28;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:22.3pt;min-height:49.7pt;width:100%;"><div style="clear:both;"></div><div style="clear:left;float:left;height:16.3pt;width:0pt;"></div><div style="clear:left;float:left;height:24.15pt;margin-left:27.75pt;margin-right:9pt;margin-top:16.3pt;width:99.08pt;z-index:251658240;"><div style="height:24.15pt;left:0pt;padding-bottom:0pt;position:relative;width:99.08pt;"><img src="aeon-20260121xex99d1001.jpg" alt="Graphic" style="height:24.15pt;width:99.08pt;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt -36pt;"><font style="font-weight:bold;margin-bottom:0pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt -36pt;"><font style="display:inline-block;width:270pt;"></font><font style="display:inline-block;width:164.9pt;"></font><b style="font-weight:bold;">PRESS RELEASE</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency. The product is approved as a biosimilar in India, Mexico, and the Philippines. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">www.aeonbiopharma.com</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">.</font><font style="font-size:12pt;"> </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:12pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;">Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or AEON&#8217;s future financial or operating performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, the satisfaction of remaining closing conditions for the PIPE financing, regulatory developments, and other risks described in the Company&#8217;s filings with the Securities and Exchange Commission.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Contacts </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Investor Contact: </b><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';">Laurence Watts</font><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';">New Street Investor Relations</font><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';">+1 619 916 7620</font><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';">laurence@newstreetir.com</font><font style="font-family:'Calibri','Helvetica','sans-serif';"> </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Source: AEON Biopharma</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-size:11pt;"><a name="TrailerStart"></a></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:8pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.28;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>aeon-20260121xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 aeon-20260121xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  Q ,<# 2(  A$! Q$!_\0
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M9KR;K%!*PY4D?>91@8' QU[5Y)XHNM3U/Q3J$VI1R+JDMPWFQD$,KYQM ]N
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5!%%%%>C#X%Z'YYCO][J_XI?FS__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>aeon-20260121.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/21/2026 6:24:00 PM-->
<!--Modified on: 1/21/2026 6:24:00 PM-->
<xsd:schema targetNamespace="http://www.aeonbiopharma.com/20260121" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:aeon="http://www.aeonbiopharma.com/20260121">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="aeon-20260121_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aeon-20260121_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aeon-20260121_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.aeonbiopharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>aeon-20260121_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/21/2026 6:24:00 PM-->
<!--Modified on: 1/21/2026 6:24:00 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.aeonbiopharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="aeon-20260121.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://www.aeonbiopharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>aeon-20260121_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/21/2026 6:24:00 PM-->
<!--Modified on: 1/21/2026 6:24:00 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>aeon-20260121_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/21/2026 6:24:00 PM-->
<!--Modified on: 1/21/2026 6:24:00 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="aeon-20260121.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_639046166400016531" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_639046166400016531" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_639046166400016531" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_639046166400016531" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_639046166400016531" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_639046166400016531" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_639046166400016531" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_639046166400016531" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_639046166400016531" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_639046166400016531" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_639046166400016531" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_639046166400016531" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_639046166400016531" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_639046166400016531" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_639046166400016531" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_639046166400016531" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_639046166400016531" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_639046166400016531" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_639046166400016531" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_639046166400016531" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_639046166400016531" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_639046166400016531" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_639046166400016531" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_639046166400016531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_639046166400016531" order="24" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 21, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 21,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AEON Biopharma,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-3940478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5 Park Plaza<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite&#160;1750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">354-6499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class&#160;A Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AEON<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001837607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="aeon-20260121x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aeon-20260121.xsd</File>
    <File>aeon-20260121_def.xml</File>
    <File>aeon-20260121_lab.xml</File>
    <File>aeon-20260121_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="aeon-20260121x8k.htm">aeon-20260121x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "aeon-20260121x8k.htm": {
   "nsprefix": "aeon",
   "nsuri": "http://www.aeonbiopharma.com/20260121",
   "dts": {
    "schema": {
     "local": [
      "aeon-20260121.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "aeon-20260121_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "aeon-20260121_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aeon-20260121_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "aeon-20260121x8k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aeon-20260121x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aeon-20260121x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001837607-26-000005-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001837607-26-000005-xbrl.zip
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M>-_#A/AY&KHIN1H87E;"M8P_F_G%YXH7A=;XAJ'&V% !XNA[6M>7>3,[K>%
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M4FL?]_U"EU:32LHYX#8-!Y2[$_V@BZ'>"Q^S&CSVWH(=.FA;':!4LG"/"IZ
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ME=WH]M;KMSC9L<?M=9+T[I/COU!+ P04    " #$@#5<9RF"A@X&  "\10
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M8?DROY,;GMR0@_:+^.>^3P6Z9\.$LR#DVDG%/VF9VN5@;#7"'1U:>IVQ?/*
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MC)72)0?J/>O\EVD/=SUK+PS>_ZSKX5]02P,$%     @ Q( U7&H(:_I.)
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M":C#R\;9%;EL7)Q?7NV XEX YT7@>@&U?>([X'[K2!,A-G*1."Z12_O&&_'
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MQHUS=!B8*R;NB32(N;I4(!_YG@UL8=HG7;#U9(&'&L^MR_W3.=[G0LA-+^'
M.F(@O"A8,3=8+3;3RL),FY90["546I/-+74_HG?B=2[I.NF <: 2-!R!B$6Y
MN>$E/)%9QLGN3]Z1^Y,7SQ6SLCTU(7"&\Y -IM2MFBO+Y5Q54<-+DLD^>*]S
M5![RA66R@#O_O"1XZ>5<29-SFE*=%,.&@R%V-'DYHZBF=?S63(10QRR?$$<T
M-?/R.,B4Y2-'0P@1'-O!1ZB4H(U+QJTUC/0Y[H!H^<]A.[%GUFH<D:GI<-[$
M7LC$;TWQ"\,CFBJQLE)B[2[3C+9:4DIMVI74=JD,;*U4NAJMT"V%1^;9I@^&
MC*L\+A).5# AM7R81CA_HHB%O.@A>SQ?L&3?>#.!Y$FW1S[1WD?>BEJ0U/DY
M9(4*+D;)?%TJ^OA"TM77S]W/<#&%"ZE0*OT6N "YPR6U=WO*WBIX41:E7+XR
MM*S$(FJ&BZAZ0<EP$8F(5BAK&3)"9%0+V9SR6^'B$3G3C[(^#IZ]X75MA(,M
M3+AK +_>[+5RP^M.!2LWO+9>7;WE-05SDPW/%9^89]1%/!-ME0EE<VZG8E\'
MT$?\F7S94F!JN6O+JQI,Q\4BT$E3(8OIMY9ILQK/O,!/,Z_%>@[?PL*7<T1P
MYLPIS.P\BE%;7%$<YXO\$MP>K-A/BH1:9?V.7C<1CR<KI2MLTGDU$H,!Q2TS
M[+/D@:Z9_OR:Q(E&W>0]IN>AM$MUO\:$TCI,]OV?V\#Q#Q^$0!0[W"-]EW7?
M[5$&PH2+19*LR/?L7I8,N=#W!\N2K%<<))=0&S,-K=3FNO#1WOMZX_R,?#"=
M89_"DQQIVGI!9!-@W-PVR"7S?)X=P/-FX#5F)]PQ4A]1U^#'N15B^M/?2>J5
M3.HSJ7]:J5>V)?6/R ^,,O&HEUKFCK,15TSH(Q=<T>@LX%P!90HY<NH;OZ,2
MP2SN3(ED2N0)E4BUNCW3X8)OM;@46RUR,RKA=Y1H65(S@7[- GV$L5QR07N8
M .,SE&8TAH^ICTGW%B/[F %B&&&R2)B/U;31?R8_/ER>$L/1 YZ_MT/'33^&
MN$\#YR;V'6:099"M#MEN;<W]=9V;Y9JMF6LF,[VBJ)2VY7*IVU9IL=.F'86V
MX8,L5TJTVBEWGC37;'Y05BAKG6?_+\G::C5/SNI7UY>-+69=3F^,<MEM8+K<
M*_16WD$J*O9,#Q<L?=+'='?<LZ73P,-D:MSSZK+$-AD/X!$IXK@GIL/ZU.I&
M29<\)AT6P*T) >Z5X,W1P.\[+@S-V%!>Z@R%'BFH3Y5L%VHL+CHP>"=Z( 2'
M/]G\=06^$QU@49IOFTO/N%X^.[[MSBE/?J#O!-O%@E;,\+T]?*OE@KP@I2!#
M^"9/.UY5P>R*%;9R\F:"MZJ%ZA:.%)XR+<JK9;5/+1/]YP^YC/L$]<*CSV-\
M1HJ"M\YJ,_&J%4YO6EWQ;@#J#^/:6B"&NFKJZ-#A_98/#DV-X< [@&H= )E\
MH+;N.EW_I3'/KZB#'>2J30[GP=ER ^/)N"OCKLV-YZAOLBXXN.#L\KCO.5Z5
MQ]R-AG*?V K[+8':;O LZ9*+R%7*)T\]0ON]*,V-N-TYIK$@X#;)Z^XXQAC^
M]/V!]?[_ 5!+ P04    " #$@#5<+E:"2O1<  #O.P( &    &%E;VXM,C R
M-C Q,C%X97@Q,&0Q+FAT;>V]"W/<1I(N^E=P9W?.LF^ -$E93WH=04ORCC8\
MME>2/2?BQHT3:'0UB1$:Z,&#%.?7GWQ5558!Z&Z*$LU=]<;N6NQ&%^J9E8\O
MO_SN_SD\?%U=9E5N%LE?WO_UIV11Y_W*5%V2-R;KX-/KHKM,WM?K=58E?S5-
M4Y1E\D-3+"Y,DIR<')T>'1^=GAP>?O\=-/52?E-7+Y*3;T[A?X]/GR3'3UZ<
M/GKQ^''RZU^3@]_>OYSATY?=JH3_;[+%]]^M3)<E^676M*;[]S_]]O['PV=_
M^OZ[KNA*\_UWW]C_\K/S>G'S_7>+XBIINYO2_/N?5EES452'7;U^\>AXW9W!
M+[^!KZ-G/AY>%XON\L7)\?&?S];98E%4%X>E678O8 Q/G_C/FN+BTG]8MT57
MP&@:4V9=<66P]0WO5N^ !]?VL65==8?+;%64-R_^[7VQ,FWRL[E.WM:KK/JW
ME#^!_[:F*9;_=D9/M\4_#?0"VNS,Q^XP*XN+ZD4.ZV*:,W[K"QDL/FY?=%6T
MQ;PHB^[FQ66Q6)@*'OA?__+L]/C1V7??X(,P-^LOT+&_]VU7+&_NWK/!RN6E
MR9H7\[J[/(L7<6QMW,CF=;,PS2'\L*M7A_3ABZJNS-F=ADQ_7F5-D57=BW:5
ME>5AGJU;_OS:T-:9U^5B9-&D0[SEUA^3MBZ+1?(OQ_0_]EO9?%-?XSX;?NDG
M/3E\ O_/_L-NZ1?X(?[?R2G_ R<J2ZIL!?/T?_Y2?C@]>?SMT^??/GJ$1R>#
M([;+]DA^@''^6S@C5=W G$S,1M=D5;N$)U[TZ[5I\JS%%3M__<O/R0]%O8;3
MO\K2I*CRH^^^F4?[U(___I?2"@;>2B_4Q/)BZ@]X_9Z,GMI@1TZO\:=MD'@/
MT%(?\EJ?__7USZ]>OTK.?WZ5O'W][OWY>_@#!/.CY,W/+U___/[-[Z^3\[^=
MOWV5_/K3^<\T\>H WGV2]62*P+23 +VT']&XCT=GCCXI*A :ZHGQ[13(G.O+
MHC.'[3K+<<-<-]D:9^/M^S<O?WJ=O#FR<D?_9%&TZS*[>5%495&9PWE9YQ_.
MAK*+Q1"+N4B*S9OO?^T;$$XF$6GVQ:2MGI='3]Q4TBXXMIN ._G^TB2_EEF%
MG3UY>M8F:^ECT29=G1A6 9(.'GM9K^"JOW%/9CQT?"SK8-;S+DT:N+"+*LFJ
M1;*J0?;"I9_ (K1UU2;7EW6RRCZ8Y*!NDJPQB?FX-CEJ!1U_,4N*U;INN@R5
M#!AD4\Q[%.34$]6#9'Z3K)OZJL"CA5]@=RN8TF+19V7+BHGY1X^=JZ\K>/UE
ML4Y 48&V^PKN!IA?Z.$WT U^ZA#6] /T(X?V3=5F7=W<A,\?)?_K7TZ>')^]
MS-9%!Y/]3^RU:59MTK?P3QAR)Q-)(UN8)>P2^OR\Z0JXJ_CG__O-4?+^$J:6
MGP1U:D%=@7EK.YBK%G]1="W,>U? 7-Y0L[$H? .B4,YIA2<!KKCD_#IK%MSL
M ?X&5^GT^"S8P[QQ2$S2(/+A,?S3][^ )"FJK*2V9.]28R=G,UC"(K],YB:'
MKB=FN83EPY?75?*??7F3G)ZDW*_/U(77[@VO8'*BSAQ]-0+I"TJDU]![^<$#
M$DKO3'-5@-3YE0XYG%\6%]37TJ TF)OD J85A0?M?#B'T'+C3F&:M/W\[[!Y
MK.@HBQ5L.)8F"]/F(%O@MY>F,47U%>VD+[B5SA>KHBI:Z"/.,DFU5Z8T%_SG
M4(&_TR3?;DXGM^"?=I@'&)58%X^<_K8P><WCQ*M#M,YXR:X,BOZLE$[,8;7P
MX;/1)7IT=&+GLK?=B5^5UV7=O+":W6A'Z!306^*O6>B2<H@[(EBL[[[IO[<W
MG%4(4 '(Y"DX)0N\=.DR\K^L&_VCX(OD,H.?]]UEW8B*L#!X7T+/Y!(9GO'&
MY,9=96W*!]P>;]Q.K9$_Y>K%ST!/6)"UUPZ.O/^*GM020-W7TT, 5:*F<>"C
MP5@ZU&+ ,$A YW'MK^R'=J3RKE@PP>\+/.)KN-^5UE"))$O.+QICT-'"S:)V
MM:C7H%N1NB#:PMK(#>W6J"%3-VGZTN#<]3"GN ^XD35J9S#;\!<,OH,N&IR_
M!9SQ#"3J]!RLLAN8QZ;!:06E!O[##6:K>0'O0-4(YWV]AMN_7A5MZZ8#?E)7
M>5&B:@;_:G$;P=\FF/P$IQD4NFCD02\KV!9MFZ%&!@^O0?%;@VW6&9X9NT'#
MF71MMI-#<VKLQN6BBT=T,C@[H-D5<'<8)^&NT>D%E]&2]!7\9(Z:**BE^ !\
M9Y7?R^R*/FV2O,Q@)\*_L9.T$T#WFYR4H[W@W"8X3^]5<()5 (M&N[1>HD4"
M4J4SI@UD* L@: @?@Y^ HHOG+/DINVYQ2\!O4GKDAQHW?MT,12L=O05?H(;V
M XFD$M^*NW%=7Z/0C+8KG F847QT53=&=8]VGOIK"?^[!(G0T+^U<26[3U[S
MKI^W8&=EC3*"WF_L>(JG-W-C3FD@L,?S0@YFVX/X7SC5 )X'-:EH+_V7KJ/X
M C<&:[,UYO!*C@STT)1+^B&(TZNB[MO2S]I"2>VLHZ<Z.!Q'GUL9><@:W^^C
M"I_NL?CF=CG1MU4)Y9_O.OAQ<GZ5%26= AB/2.>]<-LLW+Z]7ZWPYWXU!VD"
M1__=)5Q\@4Q[YY6K;(%31R*0Q4_@X_@=K S67$ RL*)&$@;TR>"Y-[^G5KE#
M"0&7Z"I;F%B@Y35,&-Z6_=KJ=;_ )R@(J8_)3ZC6V4[^VA2PM^B'TC1=T(U9
MH5<JT@]5WU -M;]T Z8I #6X[4&21-UBO8BT&FQ!Y QZA>8]SHK\BMM(Y;_H
M6\M!H:0X&+55KPVVU7P 51!E:6.RM@=-AY_?W_U;C\>]WOV\X=Z:_":'IR_T
MZ7BSA&ML:?70"0=6RO<WWZ_KK.&M(UL5/X^W+WI("]I 9;9N^1)'OZSHJV:1
MPA.PHZH+V%(H5>%_P4CJ2G8]PFUQB=HYJ.\X0GP<+ >[!U/XOLI-*9'<&O:M
M**ES [MRV9=PE9J/<.D4M&,;?,/2%/1:\O'>X!L,_P&[N*IH^'#30I?[LG.:
MOM4LLOP??4&'6<X#'6YE6D[. ][><,.CO5C5'5B&&$VFE_$;^"LY+IM#A?H(
MW$=H]K-%0.^I9_?\*KUDEXT+ZV7YAXNFAH,9G5^UE.$7EZS,H$PC,21_'X^M
MN!9Z$L^7CX(8?QS#7V<7(-Y@ZWTXI*/^(BNOLYM6-M#3)T??/OVS#<>)7C1
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MST+K<PK (X2@C1>(>XM.+7-H/L*NQ VWI@7"+7G%O:'CA,H_8:! D<$M17
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M1R,D<V'4SV4O1B$Z0AV_J'KT2,$_<87,(K7*9\K^,Q)."Y>E'830;'2):1Q
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M80CFLIA+T+)*WAH$H48NZ'$D8;:B?+%5O8#E9'75L\C<C%7F4);=C6=G8_U
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MC82N#F.QUY<U!;Z6\@[>D%(.EQW$AJ4%HZ4&J<CP5(O&>4%AJ#FZ-6QY^]S
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M(G%!D:MF2B/YN1,$2Y$!3J9@STV>2<4(+]YR%9QE#F$27(Z%!WJJ](4\@X.
M7MJ,J^N%E/&?<=6$*F@>9K3*)3Q(%7;IP91AO+T;9.;MMGM(_")K#3/6-&X[
MV:@_8?Y+PZ1\^.-%S_E/Z_K:>8$\ C  VNA+W5;[]+$)8A"]R'!59,':3N\F
M'2X"R=I4YJ:5IBE'>\;^&^M8/XCC."N^4Q$&$[@4,TG=<MMRO*"UQ<N ?M2
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MT9\P'?Y6H/NV6AP2ZG!:J.1 .(>J\@WA-X;&98_;%PN$#4[2=&1L]%"I)O'
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MONXDF?6F[<PJ+'*$VPT^X"(^<'>77&M>?B<78O1"E_\2O-F2\-LL&N?6T4B
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M7Y#QSR0 :P01L)U\P\55N31WS:CEQJ@< ?;1H!R0V)]S\X+]N@;-^,95CYH
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M5()HAR="R@ H)$E$R"-NZRH^H$J)9O-S_@=9D.EQNUJ?1*7IKFU'$9>)_61
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M1QZZL0_=V(=N[$,W]BMU8^_:>ITI&7^L\_K4_Q/DI^Y?,/\/4$L! A0#%
M  @ Q( U7%&UV3AU P  U@T  !$              ( !     &%E;VXM,C R
M-C Q,C$N>'-D4$L! A0#%     @ Q( U7,L)-]OJ @  - L  !4
M     ( !I ,  &%E;VXM,C R-C Q,C%?9&5F+GAM;%!+ 0(4 Q0    ( ,2
M-5QG*8*&#@8  +Q%   5              "  <$&  !A96]N+3(P,C8P,3(Q
M7VQA8BYX;6Q02P$"% ,4    " #$@#5<%(36&:,$  "R*0  %0
M    @ $"#0  865O;BTR,#(V,#$R,5]P<F4N>&UL4$L! A0#%     @ Q( U
M7&H(:_I.)   +U@! !0              ( !V!$  &%E;VXM,C R-C Q,C%X
M.&LN:'1M4$L! A0#%     @ Q( U7"Y6@DKT7   [SL" !@
M ( !6#8  &%E;VXM,C R-C Q,C%X97@Q,&0Q+FAT;5!+ 0(4 Q0    ( ,2
M-5P:L63'YPL  /10   8              "  8*3  !A96]N+3(P,C8P,3(Q
M>&5X,3!D,BYH=&U02P$"% ,4    " #$@#5<.F'.Y/L-  !!/0  &
M        @ &?GP  865O;BTR,#(V,#$R,7AE>#DY9#$N:'1M4$L%!@     (
-  @ ' (  -"M      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>aeon-20260121x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aeon-20260121.xsd" xlink:type="simple"/>
    <context id="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837607</identifier>
        </entity>
        <period>
            <startDate>2026-01-21</startDate>
            <endDate>2026-01-21</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Tc_ZHSRv7qa6kiQXPf21NGegg_2_1">0001837607</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Tc__tyqLVL_L021-DJfCIPv5w_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Narr_ZCOiB_FG0ESmS4c1w37gug">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Narr_FK3PvGEqwUGBaE-qIUTTQg">2026-01-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Narr_i8CLeEAwzk60gLvvEpEoSQ">AEON Biopharma,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Tc_GsG4TZm3HEq-0Sj8gPOMrg_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Tc_wIul5urS3023WFlLrNpl2Q_1_2">001-40021</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Tc_O8VEWr-9_0eeCNEjbwkz_Q_1_4">85-3940478</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Narr_Iy0d0isM7kiP57tB0nmfuQ">5 Park Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Narr_LdiD9KeyGkiDqvxRHcQQbg">Suite&#160;1750</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Narr_4mSZUgEUyUGq9de_bGGmTw">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Narr_MaKykK7Bf0u7wKjxzKNcQA">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Narr_vD4tUs0VSk2XS0FYCO-5GA">92614</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Narr_Rc7nRnq8g0qEh-MjSutF3w">949</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Narr_vQrtAZE650KwVeLD4lgJ5Q">354-6499</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Narr_S-pw5RMLpUiwl_mtS0OrVQ">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Narr_4kkJL1O1GE-y_MQxudRyow">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Narr_EVLpDsRgqUOpnHbyOf7SLA">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Narr_PtTDm0dsVEK6FGjkngqknA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Tc_98HbwGEvTEebPc4rutnDLw_2_0">Class&#160;A Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Tc_G3Yw75VYyEy9I7NX4xk_eA_2_2">AEON</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Tc_obApG6l6gUy7wKI9LtAPkg_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Narr_NJO828BS0kejGfej9vfyHQ">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_21_2026_To_1_21_2026_1x2zP-1UTkmePcGmMot3XA"
      id="Narr_GVoqwnlynEmjZI58LR5iXA">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
